Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.61 - Kexin

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abetalipoproteinemia
Hypobetalipoproteinemia and abetalipoproteinemia.
Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease.
Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.
Acquired Immunodeficiency Syndrome
Serologic responses to Pneumocystis Proteins in Human Immunodeficiency Virus Patients With and Without Pneumocystis jirovecii Pneumonia.
ACTH-Secreting Pituitary Adenoma
Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma.
Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease.
Possible relevance between prohormone convertase 2 expression and tumor growth in human adrenocorticotropin-producing pituitary adenoma.
Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I--immunohistochemical study.
Acute Coronary Syndrome
A Review of the Key Clinical Trials of 2014.
Acute coronary syndromes: Low prognostic utility of measuring PCSK9 levels in ACS.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study.
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study.
Budget impact analysis of PCSK9 inhibitors costs from a community payers' perspective in Apulia, Italy.
Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study.
Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified.
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
Evaluation of plasma PCSK9 concentrations, transcript of LDL receptor, as well as the total number of monocyte LDL receptors in acute coronary syndrome patients.
Future of the Prevention and Treatment of Coronary Artery Disease.
Highlights from Selected Cardiovascular Disease Prevention Studies Presented at the 2019 European Society of Cardiology Congress.
Identifying Patients for Nonstatin Therapy.
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
Letter: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14).
Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27?979 Patients With Incident Acute Coronary Syndrome.
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology.
New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography.
PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.
PCSK9 inhibitors in secondary prevention - an opportunity for personalized therapy.
PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
PCSK9 inhibitors.
PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study.
Prognostic value of PCSK9 levels in patients with acute coronary syndromes.
Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives.
Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review.
Response: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14).
Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome.
Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction.
Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis.
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
The Evolving Future of PCSK9 Inhibitors.
The relationship between protein convertase subtilisin kexin type-9 levels and extent of coronary artery disease in patients with non-ST-elevation myocardial infarction.
The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin-Kexin Type 7 (PCSK7) Gene Are Associated with Acute Coronary Syndrome and with Plasma Concentrations of HDL-Cholesterol and Triglycerides.
Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome.
Use and role of monoclonal antibodies and other biologics in preventive cardiology.
[Improvement of outcomes in patients with recent acute coronary syndrome: the place of PCSK9 inhibitors. The Resolution of National Advisory Board].
Acute Kidney Injury
Acute Kidney Injury During Therapy With an Antisense Oligonucleotide Directed Against PCSK9.
Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.
Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.
Adenocarcinoma of Lung
PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways.
Adenoma
Chromogranin a processing in human pituitary adenomas and carcinomas: analysis with region-specific antibodies.
Immunohistochemical expressions of prohormone convertase (PC)1/3 and PC2 in carcinoids of various organs.
Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease.
Localization of prohormone convertases 1/3 and 2 in the human pituitary gland and pituitary adenomas: analysis by immunohistochemistry, immunoelectron microscopy, and laser scanning microscopy.
Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I--immunohistochemical study.
The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3.
Adenoma, Islet Cell
Immunocytochemical localization of prohormone convertase 1/3 and 2 in pancreatic islet cells and islet cell tumors.
Adrenal Cortex Neoplasms
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer.
Adrenal Insufficiency
Molecular pathogenesis of Kallmann's syndrome.
Albuminuria
PCSK9 in diabetic kidney disease.
Alveolar Bone Loss
Role of PCSK9 in the Development of Mouse Periodontitis Before and After Treatment: A Double-Edged Sword.
Alzheimer Disease
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease.
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
No genetic association between PCSK9 polymorphisms and Alzheimer's disease and plasma cholesterol level in Japanese patients.
PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's Disease.
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.
PCSK9 is Present in Human Cerebrospinal Fluid and is Maintained at Remarkably Constant Concentrations Throughout the Course of the Day.
PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway.
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.
Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease.
Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.
The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review).
The proprotein convertase PC2 is involved in the maturation of prosomatostatin to somatostatin-14 but not in the somatostatin deficit in Alzheimer's disease.
Amnesia
[How transparent is the new Dutch guideline on cardiovascular risk management?]
Amyloidosis
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis.
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.
Anemia
Immunology Update: Biologics.
Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease.
Anemia, Sickle Cell
Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease.
Aneurysm
Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.
Proprotein Convertase Subtilisin/Kexin Type 9 Is Associated with Degenerating Adipocytes in Abdominal Aortic Aneurysm.
Aneurysm, Dissecting
Ectopic Expression of PCSK9 by Smooth Muscle Cells Contributes to Aortic Dissection.
Angina, Stable
Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina.
The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina.
Angina, Unstable
Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events : A meta-analysis of randomized controlled trials.
PCSK9 Monoclonal Antibodies: An Overview.
Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.
[Clinical study FOURIER].
Anthrax
Inhibition of furin/PC-catalyzed surface and intracellular processing by small molecules.
Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.
Aortic Aneurysm
Circulating PCSK9 is lowered acutely following surgery.
Aortic Aneurysm, Abdominal
Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
Proprotein Convertase Subtilisin/Kexin Type 9 Is Associated with Degenerating Adipocytes in Abdominal Aortic Aneurysm.
Aortic Diseases
Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.
Aortic Valve Disease
Hypothesis: New PCSK9 Inhibitors May Impact Calcific Aortic Valve Disease.
PCSK9: Associated with cardiac diseases and their risk factors?
Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study.
Aortic Valve Stenosis
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.
Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis.
PCSK9 and Calcific Aortic Valve Stenosis: Moving Beyond Lipids.
PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease.
PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
Plasmatic PCSK9 Levels Are Associated with Very Fast Progression of Asymptomatic Degenerative Aortic Stenosis.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in aortic stenosis - Is this the light at the end of the tunnel for patients with aortic stenosis?
Arcus Senilis
Analysis of mutations causing familial hypercholesterolaemia in black South African patients of different ancestr.
Arenaviridae Infections
A Molecular Sensor To Characterize Arenavirus Envelope Glycoprotein Cleavage by Subtilisin Kexin Isozyme 1/Site 1 Protease.
Arrhythmias, Cardiac
PCSK9: Associated with cardiac diseases and their risk factors?
Arteriosclerosis
Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019.
Arteritis
Lipoprotein (a), arterial inflammation, and PCSK9 inhibition.
Arthritis
PCSK9 and inflammation. Maybe a role in autoimmune diseases? Focus on rheumatoid arthritis and systemic lupus erythematosus.
Arthritis, Rheumatoid
A visible light induced photoelectrochemical aptsensor constructed by aligned ZnO@CdTe core shell nanocable arrays/carboxylated g-C3N4 for the detection of Proprotein convertase subtilisin/kexin type 6 gene.
CdSe quantum dot-functionalized TiO2 nanohybrids as a visible light induced photoelectrochemical platform for the detection of proprotein convertase subtilisin/kexin type 6.
Effect of IL-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type-9 and Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients.
Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases.
Increased expression of the proprotein convertase enzyme FURIN in rheumatoid arthritis.
Inhibition of PCSK6 may play a protective role in the development of rheumatoid arthritis.
Inhibition of pro-protein convertase subtilisin/kexin type 6 has a protective role against synovitis in a rat model of rheumatoid arthritis.
Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-?: potential underlying mechanisms.
PCSK9 and inflammation. Maybe a role in autoimmune diseases? Focus on rheumatoid arthritis and systemic lupus erythematosus.
Proprotein convertase subtilisin/kexin type 6 promotes in vitro proliferation, migration and inflammatory cytokine secretion of synovial fibroblast?like cells from rheumatoid arthritis via nuclear??B, signal transducer and activator of transcription 3 and extracellular signal regulated 1/2 pathways.
Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.
[The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis].
Asthma
European drug market entries 2015 with new mechanisms of action.
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
Atherosclerosis
6th Hellenic Congress in Athens, of the Hellenic Atherosclerosis Society, on the 04-06 December 2014 Novel Pharmacologic Treatments of Familial Hypercholesterolaemia.
A cholesterol-lowering VLP vaccine that targets PCSK9.
A Comprehensive Review of Oxidative Stress as the Underlying Mechanism in Atherosclerosis and the Inefficiency of Antioxidants to Revert this Process.
A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia.
A novel light-electricity sensing method for PCSK9 detection based on s-PdNFs with multifunctional property.
A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification.
A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1?.
A wild-type mouse-based model for the regression of inflammation in atherosclerosis.
ABCC6- a new player in cellular cholesterol and lipoprotein metabolism?
Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.
Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond.
Aerobic Exercise Training Inhibits Neointimal Formation via Reduction of PCSK9 and LOX-1 in Atherosclerosis.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
An Update on the Role of PCSK9 in Atherosclerosis.
ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model.
Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels.
Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?
Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice.
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia.
Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?
Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients.
Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease.
Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects.
Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
Atherosclerosis: cell biology and lipoproteins-focus on CD40 signaling, PCSK9, and novel animal models.
Atherosclerosis: PCSK9 inhibition reduces cardiovascular events in high-risk patients.
Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.
Blood flow patterns regulate PCSK9 secretion via MyD88 mediated proinflammatory cytokines.
Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering.
Characterization of PCSK9 in the Blood and Skin of Psoriasis.
Circulating Levels of Proprotein Convertase Subtilisin Kexin Type 9 are Elevated by Fibrate Therapy: A Systematic Review and Meta-analysis of Clinical Trials.
Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population.
Comparison of cytokine changes in three different lipoprotein apheresis systems in an ex vivo whole blood model.
Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register.
Critical Role of LOX-1-PCSK9 Axis in the Pathogenesis of Atheroma Formation and Its Instability.
Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.
Di'ao Xinxuekang Capsule, a Chinese Medicinal Product, Decreases Serum Lipids Levels in High-Fat Diet-Fed ApoE-/- Mice by Downregulating PCSK9.
Dynamin-Related Protein 1 Inhibition Attenuates Cardiovascular Calcification in the Presence of Oxidative Stress.
Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9.
Effect of PCSK9 on Vascular Smooth Muscle Cell Functions: A New Player in Atherosclerosis.
Effect of Quercetin on Atherosclerosis Based on Expressions of ABCA1, LXR-? and PCSK9 in ApoE-/- Mice.
Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease.
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.
Efficacy of Shoushen granule on adenosine triphosphate binding cassette transporter A1, proprotein convertase subtilisin/kexin type 9 and toll-like receptor 4/nuclear factor kappa-B signaling pathway in ApoE-knockout mice.
Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients.
Elevated FURIN levels in predicting mortality and cardiovascular events in patients with acute myocardial infarction.
Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus.
Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.
Endothelial-Specific Overexpression of Histone Deacetylase 2 Protects Mice against Endothelial Dysfunction and Atherosclerosis.
European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.
Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome.
Experimental models of murine atherosclerosis: does perception match reality?
Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant.
Finding inhibitors for PCSK9 using computational methods.
Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE-/- mice.
Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations.
From Endothelium to Lipids, Through microRNAs and PCSK9: A Fascinating Travel Across Atherosclerosis.
Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
HSP25 Vaccination Attenuates Atherogenesis via Upregulation of LDLR Expression, Lowering of PCSK9 Levels and Curbing of Inflammation.
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control.
Inhibition of HDAC6 Activity Protects Against Endothelial Dysfunction and Atherogenesis in vivo: A Role for HDAC6 Neddylation.
Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis.
Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion.
Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors.
Lack of RAC1 in macrophages protects against atherosclerosis.
Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.
LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers.
Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.
Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 monoclonal antibodies.
Local effects of human PCSK9 on the atherosclerotic lesion.
Losses of human disease-associated genes in placental mammals.
LPA Receptor 4 deficiency attenuates experimental atherosclerosis.
Molecular Aspects of Hypercholesterolemia Treatment; Current Perspectives and Hopes.
Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia.
New concepts in the management of dyslipidaemiaa.
New developments in atherosclerosis: clinical potential of PCSK9 inhibition.
New Era of Lipid-Lowering Drugs.
New Insight on a Combination of Policosanol and 10-Dehydrogingerdione Phytochemicals as Inhibitors for Platelet Activation Biomarkers and Atherogenicity Risk in Dyslipidemic Rabbits: Role of CETP and PCSK9 Inhibition.
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-?B pathway.
NLRP3 inflammasome via IL-1? regulates PCSK9 secretion.
Novel Approaches for the Treatment of Familial Hypercholesterolemia.
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
PCSK 9: A Link Between Inflammation and Atherosclerosis.
PCSK9 and Atherosclerosis - Lipids and Beyond.
PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography.
PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering.
PCSK9 and atherosclerosis: Looking beyond LDL regulation.
PCSK9 and inflammation: a review of experimental and clinical evidence.
PCSK9 and inflammation: Role of shear stress, pro-inflammatory cytokines and LOX-1 4.
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
PCSK9 as a therapeutic target in atherosclerosis.
PCSK9 Biology and Its Role in Atherothrombosis.
PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction.
PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation.
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation.
PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis.
PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study.
PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection.
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
PCSK9 inhibition, LDL and lipopolysaccharides: a complex and "dangerous" relationship.
PCSK9 inhibitors in the current management of atherosclerosis.
PCSK9 plays a novel immunological role in the oxidized LDL-induced dendritic cell maturation and T cell activation from human blood and atherosclerotic plaque.
PCSK9 polymorphism in a Tunisian cohort: identification of a new allele, L8, and association of allele L10 with reduced coronary heart disease risk.
PCSK9 post-transcriptional regulation: Role of a 3'UTR microRNA-binding site variant in linkage disequilibrium with c.1420G.
PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middle-Aged Population: The STANISLAS Cohort.
PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages.
PCSK9 regulates the chemokine receptor CCR2 on monocytes.
PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-?B activation in THP-1-derived macrophages.
PCSK9, an enzyme turned escort protein: hepatic and extra hepatic functions.
PCSK9: A key factor modulating atherosclerosis.
PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD).
PCSK9: A new participant in lipophagy in regulating atherosclerosis?
PCSK9: A novel inflammation modulator in atherosclerosis?
PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis?
PCSK9: Regulation and Target for Drug Development for Dyslipidemia.
Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model.
Pharmacogenomics of statins and familial hypercholesterolemia.
Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.
Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis.
Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults.
Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Pre-germinated brown rice extract ameliorates high-fat diet-induced metabolic syndrome.
Primary prevention of atherosclerosis by pretreatment of low-density lipoprotein receptor knockout mice with sesame oil and its aqueous components.
Prior renovascular hypertension does not predispose to atherosclerosis in mice.
Proprotein convertase furin/PCSK3 and atherosclerosis: New insights and potential therapeutic targets.
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies.
Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus.
Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene Is a Risk Factor of Large-Vessel Atherosclerosis Stroke.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis.
Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.
Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.
Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport.
Proprotein Convertase Subtilisin/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact.
Proprotein convertases in atherogenesis.
Proprotein convertases in human atherosclerotic plaques: the overexpression of FURIN and its substrate cytokines BAFF and APRIL.
Quantitative and qualitative lipid improvement with chronic hepatitis C virus eradication using direct-acting antivirals.
Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPAR?, LXR? and ABCA1.
R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction.
Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease.
Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.
Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis-The IMPROVE Study.
Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias.
Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes.
Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor ?-mediated pathway in L02?cells.
Role of PCSK9 in lipid metabolism and atherosclerosis.
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis.
Serum protein signature of coronary artery disease in type 2 diabetes mellitus.
Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.
Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants.
Structure and function of proprotein convertase subtilisin/kexin type 9 (PCSK9) in atherosclerosis.
Structure-activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents.
Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
Targeting Filamin A Reduces Macrophage Activity and Atherosclerosis.
Targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of dyslipidemia and atherosclerosis.
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis.
The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.
The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis.
The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease.
The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process - is there a link?
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain.
Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis.
Ticagrelor suppresses oxidized low?density lipoprotein?induced endothelial cell apoptosis and alleviates atherosclerosis in ApoE?/? mice via downregulation of PCSK9.
Tracing new atherogenic properties of PCSK9: Another insight into the pathogenesis of atherosclerosis 'the Minotaur's labyrinth'.
Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.
Unlike estrogens that increase PCSK9 levels post-menopause HSP27 vaccination lowers cholesterol levels and atherogenesis due to divergent effects on PCSK9 and LDLR.
Up-regulation of PCSK6 by lipid oxidation products: A possible role in atherosclerosis.
Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.
Vaccine against PCSK9: the natural strategy from passive to active immunization for the prevention of atherosclerosis.
Variants of PCSK9 Gene Are Associated with Subclinical Atherosclerosis and Cardiometabolic Parameters in Mexicans. The GEA Project.
Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease.
Vimentin deficiency in macrophages induces increased oxidative stress and vascular inflammation but attenuates atherosclerosis in mice.
What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
[Clinical study FOURIER].
[Diagnosis and Treatment of Familial Hypercholesterolemia].
[How to deal ugly twins, LDL-cholesterol and lipoprotein (a)].
[Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
[Monogenic hypercholesterolemias: new genes, new drug targets]
Atrial Fibrillation
A Review of the Key Clinical Trials of 2014.
Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort.
Key advances in clinical cardiology.
PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.
PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation.
Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation.
Autoimmune Diseases
Furin inhibits epithelial cell injury and alleviates experimental colitis by activating the Nrf2-Gpx4 signaling pathway.
PCSK9 and inflammation. Maybe a role in autoimmune diseases? Focus on rheumatoid arthritis and systemic lupus erythematosus.
Axial Spondyloarthritis
Comment on: Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.
Comment on: Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity: reply.
Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.
Bacterial Infections
Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units.
Chemical structure and properties of low-molecular furin inhibitors.
The role of PCSK9 in infectious diseases.
Blister
Mutations in the bli-4 (I) locus of Caenorhabditis elegans disrupt both adult cuticle and early larval development.
Brain Ischemia
Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates neuronal apoptosis following focal cerebral ischemia via apolipoprotein E receptor 2 downregulation in hyperlipidemic mice.
Breast Neoplasms
A Mendelian randomization study of the effects of blood lipids on breast cancer risk.
Effects of immunization against PCSK9 in an experimental model of breast cancer.
Elevated expression of proprotein convertases alters breast cancer cell growth in response to estrogen and tamoxifen.
Key peptide processing enzymes are expressed by breast cancer cells.
Lipoic acid-induced oxidative stress abrogates IGF-1R maturation by inhibiting the CREB/furin axis in breast cancer cell lines.
Loss of Proprotein Convertase Furin in Mammary Gland Impairs proIGF1R and proIR Processing and Suppresses Tumorigenesis in Triple Negative Breast Cancer.
Loss of the proprotein convertase Furin in T cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer.
Proprotein convertase subtilisin/kexin type 6 activates the extracellular signal-regulated kinase 1/2 and Wnt family member 3A pathways and promotes in vitro proliferation, migration and invasion of breast cancer MDA-MB-231 cells.
Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.
Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor.
Carcinogenesis
Can melatonin regulate the expression of prohormone convertase 1 and 2 genes via monomeric and dimeric forms of RZR/ROR nuclear receptor, and can melatonin influence the processes of embryogenesis or carcinogenesis by disturbing the proportion of cAMP and cGMP concentrations? Theoretic model of controlled apoptosis.
Differential Processing of Neuropeptide Proprotein in Human Breast Adenocarcinoma.
Expression of PACE4 in chemically induced carcinomas is associated with spindle cell tumor conversion and increased invasive ability.
Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins.
Loss of Proprotein Convertase Furin in Mammary Gland Impairs proIGF1R and proIR Processing and Suppresses Tumorigenesis in Triple Negative Breast Cancer.
Loss of the proprotein convertase Furin in T cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer.
MMTV-cre-mediated fur inactivation concomitant with PLAG1 proto-oncogene activation delays salivary gland tumorigenesis in mice.
Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis.
Carcinoid Tumor
Immunocytochemical localization of prohormone convertase 1/3 and 2 in gastrointestinal carcinoids.
Immunohistochemical expressions of prohormone convertase (PC)1/3 and PC2 in carcinoids of various organs.
Carcinoma
Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.
Effect of ultraviolet radiation on the expression of pp38MAPK and furin in human keratinocyte-derived cell lines.
ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis.
GPR37 is processed in the N-terminal ectodomain by ADAM10 and furin.
Human carcinoma cell growth and invasiveness is impaired by the propeptide of the ubiquitous proprotein convertase furin.
Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer.
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.
Carcinoma, Hepatocellular
A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation.
Actinidia chinensis Planch root extract inhibits cholesterol metabolism in hepatocellular carcinoma through upregulation of PCSK9.
An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
Berberrubine and its analog, hydroxypropyl-berberrubine, regulate LDLR and PCSK9 expression via the ERK signal pathway to exert cholesterol-lowering effects in human hepatoma HepG2 cells.
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.
Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis.
Decreased PCSK9 expression in human hepatocellular carcinoma.
Endosomal trafficking and proprotein convertase cleavage of cis golgi protein GP73 produces marker for hepatocellular carcinoma.
Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1? pathway in HepG2 cells.
Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia.
Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.
Liver-Specific Inactivation of the Proprotein Convertase FURIN Leads to Increased Hepatocellular Carcinoma Growth.
New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma.
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma.
PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study.
Polyphenols with indirect proprotein convertase inhibitory activity.
Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report.
Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway.
Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor.
Purification, structural characterization, and PCSK9 secretion inhibitory effect of the novel alkali-extracted polysaccharide from Cordyceps militaris.
Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function.
Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.
Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
The Modulation of PCSK9 and LDLR by Supercritical CO2 Extracts of Mentha longifolia and Isolated Piperitone Oxide, an In Vitro Study.
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells.
Carcinoma, Medullary
Immunohistochemical expressions of prohormone convertase (PC)1/3 and PC2 in carcinoids of various organs.
Carcinoma, Non-Small-Cell Lung
Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Carcinoma, Squamous Cell
Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.
Effect of ultraviolet radiation on the expression of pp38MAPK and furin in human keratinocyte-derived cell lines.
Cardiomegaly
Natriuretic peptides system in the pulmonary tissue of rats with heart failure: potential involvement in lung edema and inflammation.
Cardiomyopathies
PCSK9 promotes the secretion of pro-inflammatory cytokines by macrophages to aggravate H/R-induced cardiomyocyte injury via activating NF-?B signalling.
Cardiomyopathy, Hypertrophic
New biomarker strategies to enable precision cardiovascular medicine.
Cardiovascular Diseases
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.
A cholesterol-lowering VLP vaccine that targets PCSK9.
A dual-type responsive electrochemical immunosensor for quantitative detection of PCSK9 based on n-C
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9.
A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations.
A novel light-electricity sensing method for PCSK9 detection based on s-PdNFs with multifunctional property.
A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
A Review of PCSK9 Inhibitors and their effects on cardiovascular disease.
A safety evaluation of evolocumab.
A Small Change Can Make a Big Difference: A Lesson from Evolocumab.
A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1?.
Achilles Tendon Xanthoma Thickness and Carotid Intima-Media Thickness in a Patient With Heterozygous Familial Hypercholesterolemia on PCSK9 Inhibition: A Case Report and Literature Review.
Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond.
Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody.
Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects.
Anti-inflammatory agents in peripheral arterial disease.
Anti-PCSK9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity-Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor-Binding Enhancement.
Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.
Antisense Oligonucleotides Targeting Lipoprotein(a).
Appropriate Use of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Atherosclerotic Cardiovascular Disease: Comparison of Recommendations from Different Guidelines or Consensus Around the World.
Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease.
Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition.
Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab.
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent.
Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
Blood flow patterns regulate PCSK9 secretion via MyD88 mediated proinflammatory cytokines.
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.
Calorically restricted diets decrease PCSK9 in overweight adolescents.
Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?
Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report.
Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria.
Characterization of LDLR rs5925 and PCSK9 rs505151 genetic variants frequencies in healthy subjects from northern Chile: Influence on plasma lipid levels.
Characterization of PCSK9 in the Blood and Skin of Psoriasis.
Cholesterol-Lowering Agents.
Circulating Complex of Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 in the Serum Measured by ELISA.
Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
Circulating PCSK9 concentrations are increased in postmenopausal women with the metabolic syndrome.
Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER.
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients.
Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants.
Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Correction to: Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition: A Genome-Wide Association Study and Mendelian Randomization Study in the HUNT, Norway.
Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review.
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo.
Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.
Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects.
CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia.
Development and validation of indirect and generic immunoassays to quantify free and total evolocumab in rat serum.
Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy.
Diagnostic yield of sequencing familial hypercholesterolemia genes in individuals with primary hypercholesterolemia.
Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial.
Does 24-h Activity Cycle Influence Plasma PCSK9 Concentration? A Systematic Review and Meta-Analysis.
Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease.
Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Dyslipidaemias and cardiovascular disease: Focus on the role of PCSK9 inhibitors
Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects.
Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.
Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.
Ectopic Expression of PCSK9 by Smooth Muscle Cells Contributes to Aortic Dissection.
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9.
Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial.
Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
Effective cholesterol lowering after myocardial infarction in patients with nephrotic syndrome may require a multi-pharmacological approach: a case report.
Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study.
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients.
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ?70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ?70 mg/dl despite maximal tolerated cholesterol lowering therapy.
Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases.
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association.
Erratum to: PCSK9 inhibitors in the prevention of cardiovascular disease.
Eukaryotic Ribosome as a Target for Cardiovascular Disease.
Evolocumab: Considerations for the Management of Hyperlipidemia.
Existing and emerging therapies for the treatment of familial hypercholesterolemia.
From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Functional role of gut microbiota and PCSK9 in the pathogenesis of diabetes mellitus and cardiovascular disease.
Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
Gene Transfer Induced Hypercholesterolemia in Amyloid Mice.
Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice?
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
Genetic Polymorphisms in Sepsis and Cardiovascular Disease: Do Similar Risk Genes Suggest Similar Drug Targets?
Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement.
Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.
Genotyping and Frequency of PCSK9 Variations Among Hypercholesterolemic and Diabetic Subjects.
Giant magnetoresistive-based biosensing probe station system for multiplex protein assays.
Glucocorticoid induced TNF receptor family-related protein (GITR) - A novel driver of atherosclerosis.
High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression.
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.
Hypothesis: New PCSK9 Inhibitors May Impact Calcific Aortic Valve Disease.
Identification of amino acid residues in the ligand binding repeats of LDLR important for PCSK9 binding.
Identifying Patients for Nonstatin Therapy.
Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis.
Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Indole alkaloid from Nauclea latifolia promotes LDL uptake in HepG2 cells by inhibiting PCSK9.
Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates.
Intensive LDL-cholesterol lowering therapy and neurocognitive function.
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study.
Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management.
Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.
LDL-cholesterol: The lower the better.
Lipid-Modifying Drugs: Pharmacology and Perspectives.
Lipidomic profile in patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy.
Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?
Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations.
Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.
Loss-of-function PCSK9 mutants evade the unfolded protein response sensor, GRP78, and fail to induce endoplasmic reticulum stress when retained.
Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease.
Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Mechanisms and Treatment of Dyslipidemia in Diabetes.
Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment.
Molecular analysis of the LDLR gene in coronary artery disease patients from the Indian population.
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).
Molecular Aspects of Hypercholesterolemia Treatment; Current Perspectives and Hopes.
Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort.
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4.
New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
New concepts in the management of dyslipidaemiaa.
New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
New Pharmacological Approaches to Target PCSK9.
New risk prediction models in England may lead to targeted PCSK9 inhibitor treatment, for patients with established cardiovascular disease.
Novel Approaches for the Treatment of Familial Hypercholesterolemia.
Novel Ce(III)-Metal Organic Framework with a Luminescent Property To Fabricate an Electrochemiluminescence Immunosensor.
Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture.
Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors.
Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.
Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
PCSK9 and hypercholesterolemia: Therapeutical approach.
PCSK9 and inflammatory biomarkers in the early post kidney transplantation period.
PCSK9 as a therapeutic target for cardiovascular disease.
PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia.
PCSK9 expression in the ischemic heart and its relationship to infarct size, cardiac function and development of autophagy.
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation.
PCSK9 Gene Participates in the Development of Primary Dyslipidemias.
PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.
PCSK9 inhibition 2018: riding a new wave of coronary prevention.
PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
PCSK9 inhibition and clinical cardiovascular outcomes in patients with atherosclerotic cardiovascular disease.
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.
PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads.
PCSK9 inhibition: A promise fulfilled?
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects.
PCSK9 inhibition: the way forward in the treatment of dyslipidemia.
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era.
PCSK9 inhibitors and cardiovascular disease: impact on cardiovascular outcomes.
PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.
PCSK9 inhibitors in the prevention of cardiovascular disease.
PCSK9 Inhibitors Show Value for Patients and the US Health Care System.
PCSK9 inhibitors.
PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.
PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia.
PCSK9 Inhibitors: Treating the Right Patients in Daily Practice.
PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort.
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
PCSK9 post-transcriptional regulation: Role of a 3'UTR microRNA-binding site variant in linkage disequilibrium with c.1420G.
PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies.
PCSK9: A Key Modulator of Cardiovascular Health.
PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD).
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology.
PCSK9: A novel inflammation modulator in atherosclerosis?
PCSK9: From Basic Science Discoveries to Clinical Trials.
PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice.
Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.
Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
Pharmacogenomics of statins and familial hypercholesterolemia.
Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering.
Pharmacological Management of Hyperlipidemia in Older individuals.
Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.
Plasma PCSK9 levels are unrelated to arterial stiffness in a community-based, 4.8-year prospective study.
Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224.
Potent Lys Patch-Containing Stapled Peptides Targeting PCSK9.
Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.
Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study.
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia.
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.
Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease.
Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.
Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers.
Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus.
Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience.
Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia.
Proprotein convertase subtilisin kexin9 (PCSK9): a novel target for cholesterol regulation.
Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.
Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, reality or dream in managing patients with cardiovascular disease.
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer.
Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives.
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?
Proprotein Convertase Subtilisin/Kexin Type 9 Is Associated with Degenerating Adipocytes in Abdominal Aortic Aneurysm.
Proprotein convertase subtilisin/kexin type 9: A new target molecule for gene therapy.
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.
Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
Proprotein convertases in atherogenesis.
Quantitative and qualitative lipid improvement with chronic hepatitis C virus eradication using direct-acting antivirals.
R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction.
Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction.
Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis.
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering.
Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9).
Relation of Proprotein Convertase Subtilisin/Kexin Type 9 to Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention.
Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis-The IMPROVE Study.
Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran.
Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial).
RNA Interference for the Masses? siRNA Targeting PCSK9 Promises Prevention of Cardiovascular Disease.
Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance.
Role of Bempedoic Acid in Clinical Practice.
Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.
Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature.
Role of PCSK9 in lipid metabolism and atherosclerosis.
Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention.
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.
Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population.
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Small molecule modulators of PCSK9 - A literature and patent overview.
Small molecules as inhibitors of PCSK9: Current status and future challenges.
SRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serum.
Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Stigmasterol accumulation causes cardiac injury and promotes mortality.
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
Structure-activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents.
Synthesis of Moracin C and Its Derivatives with a 2-arylbenzofuran Motif and Evaluation of Their PCSK9 Inhibitory Effects in HepG2 Cells.
The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9.
The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease.
The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population.
The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function.
The emerging landscape of peptide-based inhibitors of PCSK9.
The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience.
The Evolving Future of PCSK9 Inhibitors.
The Future of Lipid-lowering Therapy.
The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease.
The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis.
The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury.
The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
The PCSK9 decade.
The PCSK9 revolution: Current status, controversies, and future directions.
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway.
The systematic review of randomized controlled trials of PCSK9 antibodies challenges their "efficacy breakthrough" and the "lower, the better" theory.
The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model.
Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist.
Treadmill Exercise Training Modulates Hepatic Cholesterol Metabolism and Circulating PCSK9 Concentration in High-Fat-Fed Mice.
Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease.
Understanding PCSK9 and anti-PCSK9 therapies.
Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9.
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ?190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition.
What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry.
What is the impact of the 2017 cochrane systematic review and meta-analysis that evaluated the use of PCSK9 inhibitors for lowering cardiovascular disease and mortality?
What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
[Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts].
[Clinical study FOURIER].
[Current update on PCKS9 inhibitors].
[Diagnosis and Treatment of Familial Hypercholesterolemia].
[Effect of proprotein convertase subtilisin/kexin type 9 inhibitor on blood lipid profile in patients with extremely high risk atherosclerotic cardiovascular disease].
[European dyslipidemia guidelines 2019 : What is new?]
[Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
[PCSK9 inhibitors: What place in the management of dyslipidemia?]
carnitine o-palmitoyltransferase deficiency
Hypercholesterolemia treatment in a patient with family hypercholesterolemia and myopathy due to carnitine palmitoyltransferase II deficiency with PCSK9 inhibitors.
Carotid Artery Diseases
Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults.
Profiling of Atherosclerotic Lesions by Gene and Tissue Microarrays Reveals PCSK6 as a Novel Protease in Unstable Carotid Atherosclerosis.
Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis.
Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.
Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.
Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis.
Carotid Stenosis
Achilles Tendon Xanthoma Thickness and Carotid Intima-Media Thickness in a Patient With Heterozygous Familial Hypercholesterolemia on PCSK9 Inhibition: A Case Report and Literature Review.
Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis.
Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab.
What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
Cataract
A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR.
Effect of cholesterol lowering with statins or proprotein convertase subtilisin/kexin type 9 antibodies on cataracts: A meta-analysis.
Plasma proprotein convertase subtilisin/kexin type 9 inhibitors and cataract risk: A systematic review and meta-analysis.
Cerebral Hemorrhage
Effects of Inhibition or Deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on Intracerebral Hemorrhage Volumes in Mice.
Cerebrovascular Disorders
Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.
Cholelithiasis
Low-density lipoprotein cholesterol and risk of gallstone disease: a Mendelian randomization study and meta-analyses.
Cholestasis
Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease.
Chronic Limb-Threatening Ischemia
Effects of PCSK9 Inhibitor on Favorable Limb Outcomes in Patients with Chronic Limb-Threatening Ischemia.
Chronic Periodontitis
Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey.
Pcsk9 Knockout Aggravated Experimental Apical Periodontitis via LDLR.
Coinfection
Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.
HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Pneumocystis infection and the pathogenesis of chronic obstructive pulmonary disease.
Colitis
Colonic inflammation induces changes in glucose levels through modulation of incretin system.
Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates 2,4,6-trinitrobenzenesulfonic acid-induced colitis via repressing toll-like receptor 4/nuclear factor-kappa B.
Colonic Neoplasms
Abnormal expression and processing of the proprotein convertases PC1 and PC2 in human colorectal liver metastases.
Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer.
Colorectal Neoplasms
The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.
Communicable Diseases
Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases.
Indirect regulation of PCSK9 gene in inflammatory response by Porphyromonas gingivalis infection.
PCSK9: A Potential Therapeutic Target for Sepsis.
The role of PCSK9 in infectious diseases.
Confusion
PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hyperphagia and Obesity in Prader?Willi Syndrome: PCSK1 Deficiency and Beyond?
Coronary Artery Disease
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
A novel study to examine the association of PCSK9 rs505151 polymorphism and coronary artery disease in north Indian population.
A Review of the Key Clinical Trials of 2014.
ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.
Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese.
ANNALS EXPRESS: Association between plasma proprotein convertase subtilisin/kexin type 9 level and coronary artery calcification.
Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease.
Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese.
Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study.
Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina.
Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease.
Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?
Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases.
Cholesterol-Lowering Agents.
Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease.
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy.
Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study.
Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study.
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.
Coding-sequence variants are associated with blood lipid levels in 14,473 Chinese.
Common gene variants in ASGR1 gene locus associate with reduced cardiovascular risk in absence of pleiotropic effects.
Comparison of Effects of Pitavastatin Versus Pravastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Statin-Naive Patients With Coronary Artery Disease.
Correction to: Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese.
Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease.
Correlation of serum PCSK9 in CHD patients with the severity of coronary arterial lesions.
Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort.
Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan.
Drug Discovery for Coronary Artery Disease.
Effect of Coronary Artery Disease risk SNPs on serum cytokine levels and cytokine imbalance in Premature Coronary Artery Disease.
Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort.
Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.
Effect of Evolocumab on Coronary Plaque Composition.
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome.
Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease.
Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
Eligibility for PCSK-9 inhibitors treatment in acute coronary syndrome, chronic coronary artery disease and outpatient dyslipidemic patients.
Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy.
Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.
Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia.
Familial Hypercholesterolemia: Update and Review.
Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
Genetic polymorphisms that predict outcome and need for treatment in cardiovascular disease.
Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.
Genetic susceptibility to myocardial infarction and coronary artery disease.
Genetic Testing and Risk Scores: Impact on Familial Hypercholesterolemia.
Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.
Impact of a 1-year lifestyle modification program on plasma lipoprotein and PCSK9 concentrations in patients with coronary artery disease.
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Implications of GLAGOV study.
Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
Lipid lowering and Alzheimer disease risk: A mendelian randomization study.
Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.
Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?
Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes.
Molecular dynamics insights on the role ?-augmentation of the peptide N-terminus with binding site ?-hairpin of proprotein convertase subtilisin/kexin 9.
Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia.
New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.
PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography.
PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease.
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
PCSK9 E670G polymorphism increases risk of coronary artery disease in a Chinese Han population.
PCSK9 Gene E670G Polymorphism and Coronary Artery Disease: An Updated Meta-Analysis of 5,484 Subjects.
PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression and serum proteins in CAD patients.
PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study.
PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases.
PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
PCSK9 inhibitors: clinical evidence and implementation.
PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction.
PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort.
PCSK9 polymorphism in a Tunisian cohort: identification of a new allele, L8, and association of allele L10 with reduced coronary heart disease risk.
Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.
Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies.
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans.
Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are associated with coronary artery disease and cardiovascular risk factors.
Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus.
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.
Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease.
Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study.
Recent major advances in cardiovascular pharmacotherapy.
Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease.
Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.
Relation of Proprotein Convertase Subtilisin/Kexin Type 9 to Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention.
Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
Relationships between genetic polymorphisms of E670G in PCSK9 gene and coronary artery disease: a meta-analysis.
Results of the GLAGOV trial.
Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.
Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention.
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.
Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome.
Serum PCSK6 and corin levels are not associated with cardiovascular outcomes in patients undergoing coronary angiography.
Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis.
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response.
The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.
The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
The Evolving Future of PCSK9 Inhibitors.
The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan.
The predictive utility of circulating PCSK9 levels on diabetes mellitus.
The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study.
The relationship between protein convertase subtilisin kexin type-9 levels and extent of coronary artery disease in patients with non-ST-elevation myocardial infarction.
The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease.
Therapeutic Targets of Triglyceride Metabolism as Informed by Human Genetics.
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition.
Variations of the proprotein convertase subtilisin/kexin type 9 gene in coronary artery disease.
[PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
Coronary Disease
A PCSK9 variant and familial combined hyperlipidaemia.
A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
Acute-Phase Plasma PCSK9 Levels and Recurrent Cardiovascular Events in a Chinese Acute Myocardial Infarction Cohort.
Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.
An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes.
Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation.
APOE gene variants in primary dyslipidemia.
Association between PCSK9 and LDLR gene polymorphisms with coronary heart disease: Case-control study and meta-analysis.
Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks.
Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway.
Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels.
Common and Rare Gene Variants Affecting Plasma LDL Cholesterol.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Correlation of serum PCSK9 in CHD patients with the severity of coronary arterial lesions.
Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583.
Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.
Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.
E670G polymorphism of PCSK9 gene of patients with coronary heart disease among Han population in Hainan and three provinces in the northeast of China.
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort.
Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study).
Efficacy and tolerability of alirocumab in Austrian clinical practice - results of the non-interventional PEARL-AT study.
Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China.
Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids.
Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors.
Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors. Response.
From lipid locus to drug target through human genomics.
Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.
Increasing the Specificity of AAV-Based Gene Editing through Self-Targeting and Short-Promoter Strategies.
Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion.
LDLR and ApoB are Major Genetic Causes of Autosomal Dominant Hypercholesterolemia in a Taiwanese Population.
Lipid lowering with PCSK9 inhibitors.
Lipid-lowering PCSK9 sequence variants protect against coronary heart disease.
Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
Molecular biology of PCSK9: its role in LDL metabolism.
Molecular characterization of familial hypercholesterolemia in Spain.
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.
Molecular population genetics of PCSK9: a signature of recent positive selection.
Monoclonal Antibodies for Lipid Management.
Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease.
Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms.
PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
PCSK9 function and physiology.
PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions.
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction.
PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans.
PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites.
PCSK9 polymorphism in a Tunisian cohort: identification of a new allele, L8, and association of allele L10 with reduced coronary heart disease risk.
PCSK9: a convertase that coordinates LDL catabolism.
Plasma levels of PCSK9 in a large multiethnic population.
Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia.
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia.
Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene Is a Risk Factor of Large-Vessel Atherosclerosis Stroke.
Protective lipid-lowering variants in healthy older individuals without coronary heart disease.
Recent Patents on PCSK9: A New Target for Treating Hypercholesterolemia.
Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study).
Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome.
Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.
Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants.
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.
The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain.
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain.
Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia.
Using human genetics to discover new therapeutic targets for plasma lipids.
[After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9]
[Influence of PCSK9 gene E670G polymorphism on the risk of atherosclerotic coronary heart disease and plasma lipid level].
[Monogenic hypercholesterolemias: new genes, new drug targets]
[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
[Predictive value of plasma PCSK9 levels in acute myocardial infarction patients without reperfusion therapy for recurrence of cardiovascular events within 1 year].
[Recent progresses in the treatment of dyslipidemia].
Coronary Stenosis
Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction.
Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis.
COVID-19
COVID-19 and cancer: Sailing through the tides.
COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm.
Hyperlipidemia management during the COVID-19 pandemic: PCSK9 inhibitors to enhance the antiviral action of interferon.
Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK.
May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia.
Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
Cystic Fibrosis
Proprotein Convertase Subtilisin/Kexin type 9 affects insulin but not lipid metabolism in cystic fibrosis.
Deafness
Treating hypercholesterinemia in a patient with maternally inherited diabetes and deafness (MIDD) by the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab.
Dementia
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.
PCSK9 is Increased in Cerebrospinal Fluid of Individuals With Alcohol Use Disorder.
PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort.
Dementia, Vascular
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Dengue
Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes.
How Do Enveloped Viruses Exploit the Secretory Proprotein Convertases to Regulate Infectivity and Spread?
Luteolin restricts dengue virus replication through inhibition of the proprotein convertase furin.
The role of PCSK9 in infectious diseases.
Dermatitis
Involvement of ?-Melanocyte-Stimulating Hormone-Thromboxane A2 System on Itching in Atopic Dermatitis.
Diabetes Mellitus
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
An update on PCSK9 inhibitors- pharmacokinetics, drug interactions and toxicity.
Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients.
Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.
Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice.
Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study.
Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis.
Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.
Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease.
Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.
Endogenous PCSK9 may influence circulating CD45neg/CD34bright and CD45neg/CD34bright/CD146neg cells in patients with type 2 diabetes mellitus.
Functional role of gut microbiota and PCSK9 in the pathogenesis of diabetes mellitus and cardiovascular disease.
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations.
Identification of a Small Molecule That Selectively Inhibits Mouse PC2 over Mouse PC1/3: A Computational and Experimental Study.
Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.
Lipid-Lowering Efficacy and Safety of Alirocumab in Patients with or without Diabetes: A Sub-Analysis of ODYSSEY COMBO II.
Long-Term Follow-up of a Case with Proprotein Convertase 1/3 Deficiency: Transient Diabetes Mellitus with Intervening Diabetic Ketoacidosis During Growth Hormone Therapy.
Medical Management for Secondary Stroke Prevention.
Obesity Associated with Type 2 Diabetes Mellitus Is Linked to Decreased PC1/3 mRNA Expression in the Jejunum.
PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.
PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.
PCSK9: Associated with cardiac diseases and their risk factors?
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.
Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality.
Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.
Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus.
Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies.
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
Safety and Tolerability of PCSK9 Inhibitors: Current Insights.
Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Secondary prevention of cardiovascular diseases: current state of the art.
Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review.
Susceptibility of ApoB and PCSK9 Genetic Polymorphisms to Diabetic Kidney Disease Among Chinese Diabetic Patients.
The effect of proprotein convertase subtilisin-kexin type 9 and its inhibition on glucose metabolism and cardiovascular risk. We should do better the second time after statins.
The predictive utility of circulating PCSK9 levels on diabetes mellitus.
Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.
What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
[Does "LDL hypothesis" also apply to patients with diabetes?].
[Primary prevention of coronary heart disease : Evidence-based drug treatment].
Diabetes Mellitus, Type 1
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients.
Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.
Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1).
PCSK9 Is Increased in Youth With Type 1 Diabetes.
Diabetes Mellitus, Type 2
Acute and chronic impact of bariatric surgery on plasma LDL cholesterol and PCSK9 levels in patients with severe obesity.
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes.
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Association between the rs615563 variant of PCSK9 gene and circulating lipids and Type 2 diabetes.
Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study.
Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
Association of the prohormone convertase 2 gene (PCSK2) on chromosome 20 with NIDDM in Japanese subjects.
Can LDL cholesterol be too low? Possible risks of extremely low levels.
Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?
Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders.
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.
Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes.
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study.
Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice.
Combined intake of glucose-and lipid-lowering medications further elevates plasma levels of PCSK9 in type 2 diabetes patients.
Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.
Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
Effect of Physical Activity on Plasma PCSK9 in Subjects With High Risk for Type 2 Diabetes.
Endogenous PCSK9 may influence circulating CD45neg/CD34bright and CD45neg/CD34bright/CD146neg cells in patients with type 2 diabetes mellitus.
Functional analysis of PCSK2 coding variants: A founder effect in the Old Order Amish population.
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.
LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue.
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.
Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects.
Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.
Obesity Associated with Type 2 Diabetes Mellitus Is Linked to Decreased PC1/3 mRNA Expression in the Jejunum.
PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
PCSK9 inhibition and type 2 diabetes.
PCSK9 inhibition in type 2 diabetes: so far so good, but not there yet.
PCSK9 inhibitors for the management of dyslipidemia in people with Type 2 Diabetes: How low is too low?
PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy.
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.
Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.
Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus.
Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes.
Prohormone convertase 1 in obesity, gestational diabetes mellitus, and NIDDM: no evidence for a major susceptibility role.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years.
Proprotein Convertase Subtilisin/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact.
Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.
Response to Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.
Susceptibility of ApoB and PCSK9 Genetic Polymorphisms to Diabetic Kidney Disease Among Chinese Diabetic Patients.
The association between impaired proinsulin processing and type 2 diabetes mellitus in non-obese Japanese individuals.
The effect of proprotein convertase subtilisin-kexin type 9 and its inhibition on glucose metabolism and cardiovascular risk. We should do better the second time after statins.
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
The predictive utility of circulating PCSK9 levels on diabetes mellitus.
Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.
[A near future of treatment of dyslipidemia in type 2 diabetics].
[Primary prevention of coronary heart disease : Evidence-based drug treatment].
Diabetes, Gestational
Prohormone convertase 1 in obesity, gestational diabetes mellitus, and NIDDM: no evidence for a major susceptibility role.
Diabetic Ketoacidosis
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Long-Term Follow-up of a Case with Proprotein Convertase 1/3 Deficiency: Transient Diabetes Mellitus with Intervening Diabetic Ketoacidosis During Growth Hormone Therapy.
Diabetic Nephropathies
PCSK9 in diabetic kidney disease.
Susceptibility of ApoB and PCSK9 Genetic Polymorphisms to Diabetic Kidney Disease Among Chinese Diabetic Patients.
Drug-Related Side Effects and Adverse Reactions
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.
Dwarfism
Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects.
Dyslexia
PCSK6 is associated with handedness in individuals with dyslexia.
The handedness-associated PCSK6 locus spans an intronic promoter regulating novel transcripts.
Dyslipidemias
A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism.
Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond.
Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia.
AMCP Partnership Forum: Driving New Advances in Dyslipidemia Management.
An oral antisense oligonucleotide for PCSK9 inhibition.
An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Antisense Oligonucleotides for the Treatment of Dyslipidemia.
Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.
Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia.
Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology.
Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia.
Chronic kidney disease as a cardiovascular risk factor.
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.
Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidemia in patients with high cardiovascular risk.
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels Predict Future Cardiovascular Event Risks in Hemodialyzed Black African Patients.
Concordance of two multiple analytical approaches demonstrate that interaction between BMI and ADIPOQ haplotypes is a determinant of LDL cholesterol in a general French population.
Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis.
Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.
Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapeutics.
Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice.
Diabetes, Lipids, and CV Risk.
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.
Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9, LDLR, and plasma lipids in mouse and rhesus monkey.
Dyslipidemia: blockbuster therapies are on the horizon.
Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease.
Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
Effects of the prosegment and PH on the activity of PCSK9: evidence for additional processing events.
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update.
Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease.
Erratum to: Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome.
Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia.
Expression of LDLRs (Low-Density Lipoprotein Receptors), Dyslipidemia Severity, and Response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Homozygous Familial Hypercholesterolemia: Connecting the Dots.
Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: Integration and evolution of genetic diagnosis.
Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein.
Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
Genetics for the Identification of Lipid Targets Beyond PCSK9.
Genetics of Dyslipidemia and Ischemic Heart Disease.
Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Hypothesis: New PCSK9 Inhibitors May Impact Calcific Aortic Valve Disease.
Impact of 3'UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot study.
Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis.
Independent Link Between Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and FABP4 in a General Population Without Medication.
Inhibition of Aortic Calcification by Policosanol in Dyslipidemic Rabbits Is Enhanced by Pentoxifylline: Potential Role of PCSK9.
Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
Inverse relationship between LDL cholesterol and PCSK9 plasma levels in dyslipidemic cynomolgus monkeys: effects of LDL lowering by ezetimibe in the absence of statins.
Key advances in clinical cardiology.
Knowledge of PCSK9 and Continued Educational Gaps: Evaluating the Impact of Continuing Medical Education.
Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity.
Lipid Management in Diabetes with a Focus on Emerging Therapies.
Lipid-lowering therapy: Guidelines to precision medicine.
Lipoprotein apheresis: state of the art and novelties.
Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.
Mechanisms and Treatment of Dyslipidemia in Diabetes.
Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia.
Monocyte Chemoattractant Protein-1 Is an Independent Predictor of Coronary Artery Ectasia in Patients with Acute Coronary Syndrome.
New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?
New hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: analysis of the epidermal growth factor-like repeat A docking site using WaterMap.
New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C.
Novel insights into the pathological mechanisms of metabolic related dyslipidemia.
Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
Pathology of metabolically-related dyslipidemia.
PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease.
PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia.
PCSK9 and its modulation.
PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia.
PCSK9 as a therapeutic target for cardiovascular disease.
PCSK9 as a therapeutic target of dyslipidemia.
PCSK9 Gene Participates in the Development of Primary Dyslipidemias.
PCSK9 in chronic kidney disease.
PCSK9 inhibition: the way forward in the treatment of dyslipidemia.
PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
PCSK9 inhibitors for the management of dyslipidemia in people with Type 2 Diabetes: How low is too low?
PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis.
PCSK9 inhibitors for treating hypercholesterolemia.
PCSK9: Regulation and Target for Drug Development for Dyslipidemia.
Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.
Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.
Progress in finding pathogenic DNA copy number variations in dyslipidemia.
Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibition: A Lipocrinologic Review.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese rats.
Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia.
Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus.
Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review.
Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial.
Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and United Kingdom.
Relation between proprotein convertase subtilisin/kexin type 9 and directly measured low-density lipoprotein cholesterol.
Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population.
Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias.
Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor ?-mediated pathway in L02?cells.
Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature.
Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.
Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis.
State of the art in diagnostics of ischemic heart disease and current recommended therapeutic approach.
Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands.
Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort.
Targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of dyslipidemia and atherosclerosis.
The comparative effects of high dose atorvastatin and proprotein convertase subtilisin/kexin type 9 inhibitor on the mitochondria of oxidative muscle fibers in obese-insulin resistant female rats.
The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.
The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
The PCSK9 decade.
The proprotein convertases are potential targets in the treatment of dyslipidemia.
The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model.
The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727 McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase Subtilisin/Kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012. [Epub ahead of print].
Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis.
Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs.
Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.
Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.
Understanding PCSK9 and anti-PCSK9 therapies.
Unending saga of fighting cholesterol: Evacetrapib is another fallen warrior.
Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure.
Update of Clinical Trials of Anti-PCSK9 Antibodies.
Update on PCSK9 therapies for the treatment of dyslipidemia.
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.
Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.
What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry.
[A near future of treatment of dyslipidemia in type 2 diabetics].
[Diabetic Dyslipidemia].
[News in lipid lowering treatment].
[PCSK9 inhibitors in hypercholesterolemia : New hope for patients with diabetes mellitus?]
[The new lipid-lowering drugs: focus on monoclonal antibodies].
[UPDATED ISRAELI GUIDELINES FOR THE TREATMENT OF DYSLIPIDEMIA 2020].
Dyspnea
Differential Expression of PCSK9 Modulates Infection, Inflammation and Coagulation in a Murine Model of Sepsis.
Embolic Stroke
Medical Management for Secondary Stroke Prevention.
Embolism
Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody: a case report.
Encephalitis
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
PCSK9 and the Gut-Liver-Brain Axis: A Novel Therapeutic Target for Immune Regulation in Alcohol Use Disorder.
Endometrial Neoplasms
Measuring PC activity in endocervical swab may provide a simple and non-invasive method to detect endometrial cancer in post-menopausal women.
Endometriosis
Lack of varied endometrial expression of proprotein convertase 6 in infertile women with minimal grade endometriosis and idiopathic infertility.
Endotoxemia
Curcumin Protects Against Intestinal Origin Endotoxemia in Rat Liver Cirrhosis by Targeting PCSK9.
Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 Ameliorates Liver Fibrosis via Mitigation of Intestinal Endotoxemia.
Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort.
PCSK9 decreases during experimental endotoxemia.
Relationship of Zonulin with Serum PCSK9 Levels after a High Fat Load in a Population of Obese Subjects.
Erectile Dysfunction
R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction.
Esophageal Neoplasms
Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.
Esophageal Squamous Cell Carcinoma
Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.
Essential Hypertension
Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population.
Fatty Liver
Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice.
E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver.
Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver.
Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis.
Molecular diagnosis of hypobetalipoproteinemia: an ENID review.
Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice.
PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD.
Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function.
The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
Fetal Growth Retardation
Fetal gender and gestational age differentially affect PCSK9 levels in intrauterine growth restriction.
Genetic Diseases, Inborn
Cholesterol oversynthesis markers define familial combined hyperlipidemia versus other genetic hypercholesterolemias independently of body weight.
Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement.
Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives.
Homozygous autosomal dominant hypercholesterolemia: prevalence, diagnosis, and current and future treatment perspectives.
Hyperphagia and Obesity in Prader?Willi Syndrome: PCSK1 Deficiency and Beyond?
Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation.
Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.
[Homozygous hypercholesterolemia - new therapeutic options in cases with complete lack of LDL- receptor].
Glioblastoma
Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes.
Glioma
Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes.
Paclitaxel treatment and PC1/3 knockdown in macrophages is a promising anti-glioma strategy as revealed by proteomics and cytotoxicity studies.
PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways.
The Role of a Proprotein Convertase Inhibitor in Reactivation of Tumor-Associated Macrophages and Inhibition of Glioma Growth.
Ubiquitin ligase RNF5 serves an important role in the development of human glioma.
Glucagonoma
Insulin and Glucagon mRNA Expression and Prohormone Convertase Immunoreactivity in Normal and Neoplastic Pancreatic Endocrine Tissue.
Glucose Intolerance
A common variant upstream of the PAX6 gene influences islet function in man.
Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study.
Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance.
Hypercholesterolemia: The role of PCSK9.
PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.
Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease.
Glycogen Storage Disease Type V
Hypercholesterolemia treated with a PCSK9 inhibitor in a patient with ischemic heart disease and McArdle disease.
Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors.
Gram-Negative Bacterial Infections
Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality.
Heart Diseases
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.
Mutation detection in Croatian patients with familial hypercholesterolemia.
PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
PCSK9 inhibition--a new thrust in the prevention of heart disease: genetics does it again.
PCSK9: Associated with cardiac diseases and their risk factors?
Small Molecule Inhibitors of the PCSK9·LDLR Interaction.
Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.
Targeting PCSK9 for the treatment of hypercholesterolemia.
Heart Failure
Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure.
European drug market entries 2015 with new mechanisms of action.
Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study.
Key advances in clinical cardiology.
Natriuretic peptides system in the pulmonary tissue of rats with heart failure: potential involvement in lung edema and inflammation.
PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction.
PCSK9: Associated with cardiac diseases and their risk factors?
Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.
Recent major advances in cardiovascular pharmacotherapy.
Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation.
Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review.
Heart Failure, Diastolic
Key advances in clinical cardiology.
Hematologic Neoplasms
Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis.
Hemorrhagic Stroke
Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk.
Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors.
Hepatitis
HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Hepatitis B
[Hepatitis B virus-mediated effects on host expression of the proprotein convertase Furin].
Hepatitis C
Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
Early use of PCSK9 inhibitor therapy after heart transplantation from a hepatitis C virus positive donor.
Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level.
Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.
Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity.
HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications.
PCSK9 and infection: A potentially useful or dangerous association?
PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression.
PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma.
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A.
Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.
Hepatitis C, Chronic
PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism.
Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy.
Hepatitis, Chronic
PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma.
Hepatoblastoma
Silibinin A decreases statin?induced PCSK9 expression in human hepatoblastoma HepG2 cells.
Herpes Zoster
Mutation of a conserved hydrophobic patch prevents incorporation of ZP3 into the zona pellucida surrounding mouse eggs.
HIV Infections
HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
PCSK9 and inflammation. Maybe a role in autoimmune diseases? Focus on rheumatoid arthritis and systemic lupus erythematosus.
PCSK9 in HIV infection: New opportunity or red herring?
Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
Homozygous Familial Hypercholesterolemia
A case of autosomal recessive hypercholesterolemia responsive to proprotein convertase subtilisin/kexin 9 inhibition.
A new variant (c.1A>G) in LDLRAP1 causing autosomal recessive hypercholesterolemia: Characterization of the defect and response to PCSK9 inhibition.
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.
Characterisation of LDL receptor gene mutations in a North Indian cohort of children with homozygous familial hypercholesterolaemia.
Comparison of cytokine changes in three different lipoprotein apheresis systems in an ex vivo whole blood model.
Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects.
Effect of the PCSK9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia.
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High-Dose Statin Therapy.
Evolocumab: Considerations for the Management of Hyperlipidemia.
Expression of LDLRs (Low-Density Lipoprotein Receptors), Dyslipidemia Severity, and Response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Homozygous Familial Hypercholesterolemia: Connecting the Dots.
Familial hypercholesterolemia with multiple large tendinous xanthomas and advanced coronary artery atherosclerosis.
Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
Homozygous familial hypercholesterolemia in a young woman with dual gene mutations of low-density lipoprotein receptor and proprotein convertase subtilisin/kexin type 9.
Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment.
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis.
Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
Novel therapies for familial hypercholesterolemia.
PCSK9 inhibition for autosomal recessive hypercholesterolemia.
PCSK9 Inhibitors for Homozygous Familial Hypercholesterolemia: Useful But Seldom Sufficient.
PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.
The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) study.
The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels.
The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia.
Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain.
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).
What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?
[Genetic predisposition to dyslipidemia].
[PCSK9 inhibitors : Current clinical relevance].
[TREATMENT OF HOMOZYGOTES OF FAMILIAL HYPERCHOLESTEROLEMIA: RECOMMENDATIONS OF THE ISRAELI SOCIETY OF ATHEROSCLEROSIS].
Hypercholesterolemia
12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia?- Data From a Real-World Observational Study of Evolocumab in Japan.
A case of autosomal recessive hypercholesterolemia responsive to proprotein convertase subtilisin/kexin 9 inhibition.
A cholesterol-lowering VLP vaccine that targets PCSK9.
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes.
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree.
A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia.
A new variant (c.1A>G) in LDLRAP1 causing autosomal recessive hypercholesterolemia: Characterization of the defect and response to PCSK9 inhibition.
A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.
A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
A RARE CASE OF STATIN-INDUCED NECROTIZING AUTOIMMUNE MYOPATHY.
A rare STAP1 mutation incompletely associated with familial hypercholesterolemia.
A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
A Review of PCSK9 Inhibitors and their effects on cardiovascular disease.
A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia.
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol.
AAV8-mediated overexpression of mPCSK9 in liver differs between male and female mice.
Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.
Activation of pregnane X receptor induces atherogenic lipids and PCSK9 by a SREBP2-mediated mechanism.
Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.
Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study.
Alirocumab: targeting PCSK9 to treat hypercholesterolemia.
An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels.
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells.
Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia.
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.
APOE p.Leu167del mutation in familial hypercholesterolemia.
Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
Artificial Platelets for Efficient siRNA Delivery to Clear "Bad Cholesterol".
Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting.
Berberine decreases PCSK9 expression in HepG2 cells.
Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation.
Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.
Bile acid synthesis precursors in subjects with genetic hypercholesterolemia negative for LDLR/APOB/PCSK9/APOE mutations. Association with lipids and carotid atherosclerosis.
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.
Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor.
Blood flow patterns regulate PCSK9 secretion via MyD88 mediated proinflammatory cytokines.
Butein Synergizes with Statin to Upregulate Low-Density Lipoprotein Receptor Through HNF1?-Mediated PCSK9 Inhibition in HepG2 Cells.
Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering.
Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and its Specific Treatment with Alirocumab, a PCSK9 Monoclonal Antibody.
Characterization of novel mutations in the catalytic domain of the PCSK9 gene.
Cholesterol oversynthesis markers define familial combined hyperlipidemia versus other genetic hypercholesterolemias independently of body weight.
Chronic alcohol consumption disrupted cholesterol homeostasis in rats: down-regulation of low-density lipoprotein receptor and enhancement of cholesterol biosynthesis pathway in the liver.
Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidemia in patients with high cardiovascular risk.
Clinical aspects of PCSK9.
Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.
Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia.
Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors.
Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome.
Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.
Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.
Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians.
Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects.
Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients.
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation.
Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.
Design of a Controlled Trial of Cascade Screening for Hypercholesterolemia: The (CASH) Study.
Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy.
Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
Differences in allele frequencies of autosomal dominant hypercholesterolemia SNPs in the Malaysian population.
Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.
Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease.
Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9.
Dyslipidemia and cardiovascular health in childhood nephrotic syndrome.
Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing.
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).
Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.
Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.
Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels.
Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations.
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
Efficacy and safety of different doses of alirocumab in reducing low-density lipoprotein cholesterol levels: a network meta-analysis.
Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome.
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update.
Efficacy and tolerability of alirocumab in Austrian clinical practice - results of the non-interventional PEARL-AT study.
Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia.
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.
Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy.
Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy.
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association.
Erratum: Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
Evaluation of two approaches to lysosomal acid lipase deficiency patient identification: An observational retrospective study.
Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, promotes angiogenesis in vitro.
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Exploring Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Autoproteolysis Process by Molecular Simulations: Hints for Drug Design.
Expression and localization of PCSK9 in rat hepatic cells.
Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant.
Familial hypercholesterolemia with multiple large tendinous xanthomas and advanced coronary artery atherosclerosis.
Familial Hypercholesterolemia: Update and Review.
Fatal Recurrent Staphylococcus aureus Infection in a Patient With an Aortic Endostent Under Alirocumab.
Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia.
From Endothelium to Lipids, Through microRNAs and PCSK9: A Fascinating Travel Across Atherosclerosis.
Functional analysis of sites within PCSK9 responsible for hypercholesterolemia.
Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.
Genetic variants in PCSK9 affect the cholesterol level in Japanese.
Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine.
Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome.
Genomic characterization of two deletions in the LDLR gene in Tunisian patients with familial hypercholesterolemia.
Gingival Ischemia and Petechiae in a Patient Medicated With PCSK9 Inhibitor for Hypercholesterolemia: An Adverse Drug Event?
Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.
Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9).
High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.
Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives.
Homozygous autosomal dominant hypercholesterolemia: prevalence, diagnosis, and current and future treatment perspectives.
Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment.
Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.
Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
Hypercholesterolemia treated with a PCSK9 inhibitor in a patient with ischemic heart disease and McArdle disease.
Hypercholesterolemia treatment in a patient with family hypercholesterolemia and myopathy due to carnitine palmitoyltransferase II deficiency with PCSK9 inhibitors.
Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9.
Hypercholesterolemia: The role of PCSK9.
Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults.
Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
Identification and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy.
Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia.
Identification of mutations in the apolipoprotein B-100 gene and in the PCSK9 gene as the cause of hypocholesterolemia.
IL-13-driven alterations in hepatic cholesterol handling contributes to hypercholesterolemia in a rat model of minimal change disease.
Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
Improved endothelial function after short-term therapy with evolocumab.
In Vitro Assays for the Discovery of PCSK9 Autoprocessing Inhibitors.
In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
Inclisiran for the treatment of dyslipidemia.
Inclisiran in dyslipidemia.
Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis.
Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control.
Increased Valency Improves Inhibitory Activity of Peptides Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
Increasing serum half-life and extending cholesterol lowering in vivo by engineering an antibody with pH-sensitive binding to PCSK9.
Independent Link Between Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and FABP4 in a General Population Without Medication.
Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.
Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.
Insights into pharmacological mechanisms of polydatin in targeting risk factors-mediated atherosclerosis.
In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.
Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
Keep recycling going: New approaches to reduce LDL-C.
Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.
LDL-receptor mutations in Europe.
LDLR and ApoB are Major Genetic Causes of Autosomal Dominant Hypercholesterolemia in a Taiwanese Population.
Lipid Lowering Drugs: Present Status and Future Developments.
Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE.
Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.
Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9.
LOSS- AND GAIN-OF-FUNCTION PCSK9 VARIANTS: CLEAVAGE SPECIFICITY, DOMINANT NEGATIVE EFFECTS AND LDLR DEGRADATION.
Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia: A case report.
Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation.
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.
Low prevalence of mutations in known Loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort.
Low-density lipoprotein cholesterol lowering treatment: the current approach.
Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
Lupin Peptides Modulate the Protein-Protein Interaction of PCSK9 with the Low Density Lipoprotein Receptor in HepG2 Cells.
Macrophage-Associated Lipin-1 Enzymatic Activity Contributes to Modified Low-Density Lipoprotein-Induced Proinflammatory Signaling and Atherosclerosis.
Mechanisms of disease: genetic causes of familial hypercholesterolemia.
Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol.
Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes.
MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis.
microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
Moderate phenotypic expression of familial hypercholesterolemia in Tunisia.
Modulation of cholesterol transport by maternal hypercholesterolemia in human full-term placenta.
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).
Molecular Aspects of Hypercholesterolemia Treatment; Current Perspectives and Hopes.
Molecular biology of PCSK9: its role in LDL metabolism.
Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrent LDLR mutations.
Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.
Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia.
Molecular Spectrum of Autosomal Dominant Hypercholesterolemia in France.
Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9.
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.
Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure.
Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.
New Pharmacological Approaches to Target PCSK9.
Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia.
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C.
Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease.
Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.
Novel RNAi-Based Therapies for Atherosclerosis.
OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events.
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
PCSK9 and hypercholesterolemia: Therapeutical approach.
PCSK9 and its modulation.
PCSK9 antibodies for the treatment of hypercholesterolemia.
PCSK9 expression in the ischemic heart and its relationship to infarct size, cardiac function and development of autophagy.
PCSK9 function and physiology.
PCSK9 gene mutations and low-density lipoprotein cholesterol.
PCSK9 Gene Participates in the Development of Primary Dyslipidemias.
PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis.
PCSK9 in cholesterol metabolism: from bench to bedside.
PCSK9 in diabetic kidney disease.
PCSK9 inhibition for autosomal recessive hypercholesterolemia.
PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.
PCSK9 inhibition in patients with hypercholesterolemia.
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
PCSK9 Inhibition With Monoclonal Antibodies-Modern Management of Hypercholesterolemia.
PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).
PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk.
PCSK9 inhibition: the way forward in the treatment of dyslipidemia.
PCSK9 inhibitors for treating hypercholesterolemia.
PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.
PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia.
PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol.
PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides.
PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans.
PCSK9 Monoclonal Antibodies: An Overview.
PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
PCSK9 post-transcriptional regulation: Role of a 3'UTR microRNA-binding site variant in linkage disequilibrium with c.1420G.
PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation.
PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.
PCSK9, an enzyme turned escort protein: hepatic and extra hepatic functions.
PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study.
PCSK9: A Key Modulator of Cardiovascular Health.
PCSK9: a promising therapeutic target for dyslipidemias?
PCSK9: an emerging target for treatment of hypercholesterolemia.
PCSK9: An enigmatic protease.
PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice.
Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shot.
Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition.
Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia.
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans.
Plasma PCSK9 levels correlate with cholesterol in men but not in women.
Plasma PCSK9 preferentially reduces liver LDL receptors in mice.
Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.
Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.
Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia.
Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia.
Primary prevention of atherosclerosis by pretreatment of low-density lipoprotein receptor knockout mice with sesame oil and its aqueous components.
Prior renovascular hypertension does not predispose to atherosclerosis in mice.
Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies.
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Proprotein convertase subtilisin kexin9 (PCSK9): a novel target for cholesterol regulation.
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis.
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer.
Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia.
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Proprotein convertase subtilisin/kexin type 9: A new target molecule for gene therapy.
Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor.
Pterostilbene Increases LDL Metabolism in HL-1 Cardiomyocytes by Modulating the PCSK9/HNF1?/SREBP2/LDLR Signaling Cascade, Upregulating Epigenetic hsa-miR-335 and hsa-miR-6825, and LDL Receptor Expression.
Quantitative evaluation of the improvement in the pharmacokinetics of a nucleic acid drug delivery system by dynamic PET imaging with (18)F-incorporated oligodeoxynucleotides.
Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy.
Recent Patents on PCSK9: A New Target for Treating Hypercholesterolemia.
Regulatory Effects of Peptides from the Pro and Catalytic Domains of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) on Low-Density Lipoprotein Receptor (LDL-R).
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
Review: PCSK9 inhibitors reduce mortality but increase neurocognitive events in hypercholesterolemia.
RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form.
Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance.
Role of Lipoprotein Apheresis in Cardiovascular Disease Risk Reduction.
Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials.
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.
Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome.
Selection and characterization of human PCSK9 antibody from phage displayed antibody library.
Self-association of human PCSK9 correlates with its LDLR-degrading activity.
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.
Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review.
Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population.
Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response.
Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study.
Sirolimus Therapy Is Associated with Elevation in Circulating PCSK9 Levels in Cardiac Transplant Patients.
Small molecules as inhibitors of PCSK9: Current status and future challenges.
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.
State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications.
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
Substantial PCSK9 inactivation in ?-cells does not modify glucose homeostasis or insulin secretion in mice.
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Targeting PCSK9 for hypercholesterolemia.
Targeting PCSK9 for the treatment of hypercholesterolemia.
Targeting PCSK9 for Therapeutic Gains.
Targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of dyslipidemia and atherosclerosis.
The Cholesterol-Lowering Effect of Capsella Bursa-Pastoris Is Mediated via SREBP2 and HNF-1?-Regulated PCSK9 Inhibition in Obese Mice and HepG2 Cells.
The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women.
The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2?a monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
The immune functions of PCSK9: Local and systemic perspectives.
The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy.
The p.Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes.
The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia.
The proprotein convertases are potential targets in the treatment of dyslipidemia.
The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia.
The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
The Severe Hypercholesterolemia Phenotype: Clinical Diagnosis, Management, and Emerging Therapies.
The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727 McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase Subtilisin/Kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012. [Epub ahead of print].
Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.
Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab.
Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain.
Treatment of hypercholesterolemia with PCSK9 inhibitors in heart transplant recipients. First experience in Spain.
Universal Screening for Familial Hypercholesterolemia in Children.
Unravelling the functional significance of PCSK9.
Unusual genetic variants associated with hypercholesterolemia in Argentina.
Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure.
Up-regulation of PCSK9 gene expression and diminished level of LDL-receptor in rat liver as a potential cause of post-lipectomy hypercholesterolemia.
Update on dyslipidemia.
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.
Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
Use of Plasma Metabolomics to Analyze Phenotype-Genotype Relationships in Young Hypercholesterolemic Females.
Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors.
Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9.
Variable phenotypic expression of nonsense mutation p.Thr5* in the APOE gene.
What is the role of PCSK9 inhibitors in treating hypercholesterolemia?
What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells.
WITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management.
[After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9]
[Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
[Genetic predisposition to dyslipidemia].
[Homozygous hypercholesterolemia - new therapeutic options in cases with complete lack of LDL- receptor].
[Lipid treatment in the period COVID-19].
[Monogenic hypercholesterolemias: new genes, new drug targets]
[New agents for hypercholesterolemia].
[PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
[PCSK9 inhibitors (PCSK9i), a new opportunity for cardiovascular prevention: clinical and regulatory aspects and access to therapy.]
[PCSK9 inhibitors : Current clinical relevance].
[PCSK9 inhibitors in hypercholesterolemia : New hope for patients with diabetes mellitus?]
[PCSK9 inhibitors: new treatment to lower cholesterol].
[PCSK9: a new gene involved in familial hypercholesteremia]
[Primary prevention of coronary heart disease : Evidence-based drug treatment].
[Therapeutic algorithm for lipoprotein apheresis and PCSK9 inhibition for severe hypercholesterolemia or isolated lipoprotein(a) hyperlipoproteinemia].
Hyperglycemia
Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease.
Liver fat accumulation is associated with circulating PCSK9.
PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides.
Pre-germinated brown rice extract ameliorates high-fat diet-induced metabolic syndrome.
Regulation of prohormone convertases in hypothalamic neurons: implications for prothyrotropin-releasing hormone and proopiomelanocortin.
Rescue effect of sodium acetate in diabetes mellitus-associated testicular dysfunction is accompanied by PCSK9 modulation.
Hyperinsulinism
Aberrant corin and PCSK6 in placentas of the maternal hyperinsulinemia IUGR rat model.
Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
PCSK9 targets important for lipid metabolism.
Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.
Rescue effect of sodium acetate in diabetes mellitus-associated testicular dysfunction is accompanied by PCSK9 modulation.
Hyperlipidemia, Familial Combined
Cholesterol oversynthesis markers define familial combined hyperlipidemia versus other genetic hypercholesterolemias independently of body weight.
Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Hyperlipidemias
A case of autosomal recessive hypercholesterolemia responsive to proprotein convertase subtilisin/kexin 9 inhibition.
A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia.
A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations.
ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.
Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody.
An Update on the Role of PCSK9 in Atherosclerosis.
ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model.
Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.
Assessment and Management of Patients with Hyperlipidemia Referred for Initiation of PCSK9 Inhibitor Therapy: A Lipid Clinic Experience.
Berberrubine and its analog, hydroxypropyl-berberrubine, regulate LDLR and PCSK9 expression via the ERK signal pathway to exert cholesterol-lowering effects in human hepatoma HepG2 cells.
Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1.
Cholesterol oversynthesis markers define familial combined hyperlipidemia versus other genetic hypercholesterolemias independently of body weight.
Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice.
Contribution of aorta glycosaminoglycans and PCSK9 to hyperlipidemia in experimental rabbits: the role of 10-dehdrogingerdione as effective modulator.
Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians.
Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development.
Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia.
Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia.
Effect of Evolocumab on Lipoprotein Particles.
Effects of diet and hyperlipidemia on levels and distribution of circulating lysophosphatidic acid.
Effects of Hedan Tablet () on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study.
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
Evolocumab: Considerations for the Management of Hyperlipidemia.
Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.
Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
Guideline recommendations, clinical trial data, and new and emerging therapies.
Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression.
Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
Hyperlipidemia management during the COVID-19 pandemic: PCSK9 inhibitors to enhance the antiviral action of interferon.
Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(-/-) mice may be associated with increased PCSK9 expression.
Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors.
Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential.
Indole alkaloid from Nauclea latifolia promotes LDL uptake in HepG2 cells by inhibiting PCSK9.
Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates neuronal apoptosis following focal cerebral ischemia via apolipoprotein E receptor 2 downregulation in hyperlipidemic mice.
Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia.
Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome?
Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.
Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV.
Metabolic regulation of GLP-1 and PC1/3 in pancreatic ?-cell line.
Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
New Aromatic Compounds from the Fruiting Body of Sparassis crispa (Wulf.) and Their Inhibitory Activities on Proprotein Convertase Subtilisin/Kexin Type 9 mRNA Expression.
New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice.
Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C.
PCSK9 and triglyceride-rich lipoprotein metabolism.
PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation.
PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook.
PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia.
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes.
PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway.
PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies.
PCSK9: A key factor modulating atherosclerosis.
Pharmacological Management of Hyperlipidemia in Older individuals.
Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.
Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial.
Real-world use of PCSK9 inhibitors: A single-center experience.
Relationship of Zonulin with Serum PCSK9 Levels after a High Fat Load in a Population of Obese Subjects.
Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody: a case report.
The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review).
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors.
The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy.
The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice.
The role of PCSK9 in infectious diseases.
The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
Therapeutic Targets of Triglyceride Metabolism as Informed by Human Genetics.
Thyroid hormones: a potential ally to LDL-cholesterol-lowering agents.
Treatment of hyperlipidemia with proprotein convertase subtilisin/kexin type 9 inhibitor in a patient with nephrotic syndrome: a case report.
Umbrella Review on Non-Statin Lipid-Lowering Therapy.
Use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Statin-Associated Immune-Mediated Necrotizing Myopathy: A Case Series.
What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
[Hyperlipidemia: What role do PCSK9 inhibitors play?]
[PCSK9 as new target in hyperlipidemia treatment.]
[Recommendations of the European Society of Cardiology and the European Atherosclerosis Society on Cardiovascular Disease Prevention and Management of Dyslipidemias. for the Diagnosis of Atherosclerosis and Dyslipidemia Treatment (2016): Basic S.G.]
Hyperlipoproteinemia Type I
[Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
Hyperlipoproteinemia Type II
12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia?- Data From a Real-World Observational Study of Evolocumab in Japan.
A case of heterozygous familial hypercholesterolemia requiring strict low-density lipoprotein cholesterol management with proprotein convertase subtilisin/kexin 9 inhibitor after coronary artery bypass grafting.
A case of repetitive acute coronary syndrome in a patient with familial hypercholesterolemia.
A DNA Microarray for the Detection of Point Mutations and Copy Number Variation Causing Familial Hypercholesterolemia in Europe.
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
A new method for measurement of total plasma PSCK9 - clinical applications.
A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia.
A Novel Cause of Familial Hypercholesterolemia: PCSK9 Gene Duplication.
A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
A novel pathogenic variant of the LDLR gene in the Asian population and its clinical correlation with familial hypercholesterolemia.
A novel splice site mutation of the LDL receptor gene in a Tunisian hypercholesterolemic family.
A Novel Splice Site Variant in the LDLRAP1 Gene Causes Familial Hypercholesterolemia
A rare STAP1 mutation incompletely associated with familial hypercholesterolemia.
A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterolemia Phenotype Caused by Possibly Oligogenic Variants of the PCSK9 and ABCG5 Genes and Type I CD36 Deficiency.
A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
A review of gene- and cell-based therapies for familial hypercholesterolemia.
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol.
A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
Achilles Tendon Xanthoma Thickness and Carotid Intima-Media Thickness in a Patient With Heterozygous Familial Hypercholesterolemia on PCSK9 Inhibition: A Case Report and Literature Review.
Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
An Evidence-Based Guide to Cholesterol-Lowering Guidelines.
Analysis of Arterial Stiffness and Sexual Function after Adding on PCSK9 Inhibitor Treatment in Male Patients with Familial Hypercholesterolemia: A Single Lipid Center Real-World Experience.
Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis.
Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells.
Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
APOE p.Leu167del mutation in familial hypercholesterolemia.
Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?
Arterial stiffness improvement after adding on PCSK9 inhibitors in patients with familial hypercholesterolemia.
Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience.
Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
Association of Level of Proprotein Convertase Subtilisin/Kexin Type 9 with Intima-Media Thickness in Patients with Familial Hypercholesterolemia.
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.
Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors.
Author's reply to: Arterial stiffness improvement after adding on PCSK9 inhibitors in patients with familial hypercholesterolemia, a letter from Papaioannou and colleagues.
Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting.
Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association.
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and its Specific Treatment with Alirocumab, a PCSK9 Monoclonal Antibody.
Characterization of novel mutations in the catalytic domain of the PCSK9 gene.
Children with hypercholesterolemia of unknown cause: Value of genetic risk scores.
Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue.
Common mutations of familial hypercholesterolemia patients in Taiwan: Characteristics and implications of migrations from southeast China.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Consensus statement of professional associations on prescribing of PCSK9-inhibitors.
Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation.
Correction to: Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.
Corrigendum to PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study Volume 14, Issue 3, May-June 2020, Pages 322-330.e5.
Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects.
Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia.
Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified.
Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation.
Detection of mutations and large rearrangements of the low-density lipoprotein receptor gene in Taiwanese patients with familial hypercholesterolemia.
Differences in allele frequencies of autosomal dominant hypercholesterolemia SNPs in the Malaysian population.
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.
Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials.
Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease.
Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9.
Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects.
Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia.
Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting.
Effect of the PCSK9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia.
Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations.
Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia.
Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia.
Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience.
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.
Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High-Dose Statin Therapy.
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ?70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ?70 mg/dl despite maximal tolerated cholesterol lowering therapy.
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association.
Erratum: Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia - A study supported by Korean Society of Lipidology and Atherosclerosis.
Expression and localization of PCSK9 in rat hepatic cells.
Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant.
Familial hypercholesterolemia--epidemiology, diagnosis, and screening.
Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag.
Familial hypercholesterolemia: Detect, treat, and ask about family.
Familial hypercholesterolemia: experience from France.
Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation?
Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.
Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 (PCSK9) levels.
Fenotipo de hipercolesterolemia familiar definitivo con estudio genético negativo en Argentina.
Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice.
Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations.
Functional analysis of natural PCSK9 mutants in modern and archaic humans.
Functional analysis of new variants at the low-density lipoprotein receptor associated with familial hypercholesterolemia.
Functional analysis of PCSK9 3'UTR variants and mRNA-miRNA interactions in patients with familial hypercholesterolemia.
Functional analysis of sites within PCSK9 responsible for hypercholesterolemia.
Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: Integration and evolution of genetic diagnosis.
Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
Genetic and biochemical analyses in dyslipidemic patients undergoing LDL apheresis.
Genetic determinants of inherited susceptibility to hypercholesterolemia - a comprehensive literature review.
Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia.
Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement.
Genetic variants in PCSK9 affect the cholesterol level in Japanese.
Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor.
Genomic characterization of two deletions in the LDLR gene in Tunisian patients with familial hypercholesterolemia.
Getting Real With PCSK9 Inhibitors in Familial Hypercholesterolemia.
Healthy Individuals Carrying the PCSK9 p.R46L Variant and Familial Hypercholesterolemia Patients Carrying PCSK9 p.D374Y Exhibit Lower Plasma Concentrations of PCSK9.
Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives.
Homozygous autosomal dominant hypercholesterolemia: prevalence, diagnosis, and current and future treatment perspectives.
Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.
Identification and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy.
Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia.
Identification of mutations in the apolipoprotein B-100 gene and in the PCSK9 gene as the cause of hypocholesterolemia.
Identifying Patients for Nonstatin Therapy.
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia.
Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial.
Ineffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with Low-Density Lipoprotein Cholesterol (LDL-C) Receptor Abnormalities: A Report of 2 Cases.
Inhibition of PCSK9D374Y/LDLR Protein-Protein Interaction by Computationally Designed T9 Lupin Peptide.
Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia.
LDL-receptor mutations in Europe.
LDLR and ApoB are Major Genetic Causes of Autosomal Dominant Hypercholesterolemia in a Taiwanese Population.
Limited mutational heterogeneity in the LDLR gene in familial hypercholesterolemia in Tunisia.
Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future.
Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.
Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.
Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia.
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia: A case report.
Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation.
Low prevalence of mutations in known Loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort.
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
Low-Density Lipoprotein Receptor Gene Mutation Analysis and Structure-Function Correlation in an Omani Arab Family With Familial Hypercholesterolemia.
Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy.
Moderate phenotypic expression of familial hypercholesterolemia in Tunisia.
Molecular analysis of the LDLR gene in coronary artery disease patients from the Indian population.
Molecular basis of familial hypercholesterolemia.
Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort.
Molecular characterization of familial hypercholesterolemia in Spain.
Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrent LDLR mutations.
Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.
Molecular genetics of familial hypercholesterolemia in Israel-revisited.
Molecular Spectrum of Autosomal Dominant Hypercholesterolemia in France.
Mutation detection in Croatian patients with familial hypercholesterolemia.
Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure.
Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement.
Mutational heterogeneity in low-density lipoprotein receptor gene related to familial hypercholesterolemia in Morocco.
Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia.
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.
New biomarker strategies to enable precision cardiovascular medicine.
New drugs for treating dyslipidemia: beyond statins.
Next-generation sequencing to confirm clinical familial hypercholesterolemia.
No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia.
No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes.
Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.
Novel therapies for familial hypercholesterolemia.
Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment.
Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment.
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia.
PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia.
PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients.
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
PCSK9 as a therapeutic target for cardiovascular disease.
PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia.
PCSK9 gene mutations and low-density lipoprotein cholesterol.
PCSK9 Gene Participates in the Development of Primary Dyslipidemias.
PCSK9 in cholesterol metabolism: from bench to bedside.
PCSK9 in South African variants of familial hypercholesterolemia.
PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
PCSK9 inhibition in patients with hypercholesterolemia.
PCSK9 inhibition in the management of familial hypercholesterolemia.
PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.
PCSK9 Inhibition With Monoclonal Antibodies-Modern Management of Hypercholesterolemia.
PCSK9 Inhibition: Current Concepts and Lessons from Human Genetics.
PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report.
PCSK9 inhibitors in familial hypercholesterolemia: What is the evidence?
PCSK9 Inhibitors Show Value for Patients and the US Health Care System.
PCSK9 Monoclonal Antibodies: An Overview.
PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis.
PCSK9: a promising therapeutic target for dyslipidemias?
PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all : Editorial to: "Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/Dl or Higher" by Henry N. Ginsberg et Al.
Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
Phenotype of definite familial hypercholesterolemia with negative genetic study in Argentina.
Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.
Plaque Stabilization by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor in a Patient With Familial Hypercholesterolemia Undergoing Percutaneous Coronary Intervention.
Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.
Plasma levels of proprotein convertase subtilisin Kexin type 9 (PCSK9) and phenotypic variability in familial hypercholesterolemia.
Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia.
Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans.
Plasma PCSK9 levels correlate with cholesterol in men but not in women.
Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
Polygenic Markers in Patients Diagnosed of Autosomal Dominant Hypercholesterolemia in Catalonia: Distribution of Weighted LDL-c-Raising SNP Scores and Refinement of Variant Selection.
Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.
Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia.
Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia.
Premature coronary artery disease and familial hypercholesterolemia: need for early diagnosis and cascade screening in the Indian population.
Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers.
Progress in finding pathogenic DNA copy number variations in dyslipidemia.
Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.
Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience.
Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders.
Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia.
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
Proprotein convertase subtilisin/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia.
Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials.
Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders.
Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia.
Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia.
Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance.
Role of PCSK9 in lipid metabolism and atherosclerosis.
Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.
Screening and management of familial hypercholesterolemia.
Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India.
Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response.
Severe xanthomatosis in heterozygous familial hypercholesterolemia.
Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk.
Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.
Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants.
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.
The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.
The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population.
The efficacy of anti-PCSK9 antibodies: Results from recent trials.
The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels.
The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience.
The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c.10580 G>A: p.(Arg3527Gln).
The genetic spectrum of Familial Hypercholesterolemia in Pakistan.
The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia.
The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
The p.Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes.
The PCSK9 revolution: Current status, controversies, and future directions.
The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.
The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
The Severe Hypercholesterolemia Phenotype: Clinical Diagnosis, Management, and Emerging Therapies.
The systematic review of randomized controlled trials of PCSK9 antibodies challenges their "efficacy breakthrough" and the "lower, the better" theory.
Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies.
Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.
Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain.
Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach.
Update on the molecular biology of dyslipidemias.
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.
Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
Use of PCSK9 Inhibitor in a Mexican Boy with Compound Heterozygous Familial Hypercholesterolemia: A Case Report.
Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?
VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly.
What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
Whole-Exomes Sequencing Delineates Gene Variants Profile in a Young Saudi Male with Familial Hypercholesterolemia: Case Report.
Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia.
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells.
[After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9]
[Current update on PCKS9 inhibitors].
[Diagnosis and Treatment of Familial Hypercholesterolemia].
[ECS guidelines 2016 - dyslipidaemias].
[Familial hypercholesterolemia in the Czech Republic in 2016].
[Familial hypercholesterolemia in Tunisia.]
[Genetic predisposition to dyslipidemia].
[Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
[Introduction of PCSK9 inhibitors : New perspectives in treatment and practical implementation].
[Molecular genetics of hypercholesterolemia].
[Monoclonal antibodies in cardiovascular diseases and metabolic disorders today].
[Monogenic hypercholesterolemias: new genes, new drug targets]
[PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know].
[PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
[PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].
[PCSK9 inhibitors and dyslipidemias: an update on clinical evidence].
[PCSK9 inhibitors: What place in the management of dyslipidemia?]
[PERSONALIZED APPROACH TO LIPID-LOWERING THERAPY].
[Real-life efficacy and safety of PCSK9 inhibitors treatment: Experience in three hospitals in Asturias].
[Recommendations of the European Society of Cardiology and the European Atherosclerosis Society on Cardiovascular Disease Prevention and Management of Dyslipidemias. for the Diagnosis of Atherosclerosis and Dyslipidemia Treatment (2016): Basic S.G.]
[Severe familial hypercholesterolemia treatment].
[The new lipid-lowering drugs: focus on monoclonal antibodies].
[The relationship between genotype of familial hypercholesterolemia and the efficacy of PCSK9 inhibitors].
Hyperlipoproteinemia Type III
[Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
Hyperlipoproteinemias
Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report.
Therapeutic management of hyperlipoproteinemia (a).
Hypernatremia
Enteroendocrine Dysfunction in Two Saudi Sisters.
Hypersensitivity
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
Hypertension
A Review of the Key Clinical Trials of 2014.
Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials.
Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials.
Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients.
Association of Zinc Finger, C3HC-Type Containing 1 (ZC3HC1) rs11556924 Genetic Variant With Hypertension in a Finnish Population, the TAMRISK Study.
Cardiology clinic visit increases likelihood of evidence-based cholesterol prescribing in severe hypercholesterolemia.
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study.
Hypercholesterolemia: The role of PCSK9.
Key advances in clinical cardiology.
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies.
PCSK9: Associated with cardiac diseases and their risk factors?
Plasma PCSK9 levels are unrelated to arterial stiffness in a community-based, 4.8-year prospective study.
Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults.
Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus.
Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease.
Prior renovascular hypertension does not predispose to atherosclerosis in mice.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines.
Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody: a case report.
Targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of dyslipidemia and atherosclerosis.
The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process - is there a link?
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.
Untypical Metabolic Adaptations in Spontaneously Hypertensive Rats to Free Running Wheel Activity Includes Uncoupling Protein-3 (UCP-3) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Expression.
[Primary prevention of coronary heart disease : Evidence-based drug treatment].
[Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines.]
[Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines].
Hypertension, Pregnancy-Induced
Aberrant corin and PCSK6 in placentas of the maternal hyperinsulinemia IUGR rat model.
Hypertension, Renovascular
Prior renovascular hypertension does not predispose to atherosclerosis in mice.
Hyperthyroidism
Association of serum proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) level with thyroid function disorders.
Regulation of prohormone convertases in hypothalamic neurons: implications for prothyrotropin-releasing hormone and proopiomelanocortin.
Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans.
Hypertriglyceridemia
A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes.
Dyslipidemia and cardiovascular health in childhood nephrotic syndrome.
Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome.
Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C.
Progress in finding pathogenic DNA copy number variations in dyslipidemia.
Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain.
[ANMCO Position paper: New perspectives on the role of n-3 polyunsaturated fatty acids in cardiovascular prevention].
[The triglyceride-lowering effects of PCSK9 inhibitor differ in patients with different baseline triglyceride levels].
Hypoadrenocorticism, Familial
Genetics of hypogonadotropic hypogonadism.
Hypogonadotropic hypogonadism.
Hypoalphalipoproteinemias
Progress in finding pathogenic DNA copy number variations in dyslipidemia.
Hypobetalipoproteinemias
A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene.
A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol.
Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature.
Hypobetalipoproteinemia and abetalipoproteinemia.
Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease.
Low-Density Lipoprotein Cholesterol (LDL-C): How Low?
Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia.
Phenotypic Differences Between Polygenic and Monogenic Hypobetalipoproteinemia.
Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders.
Update on the molecular biology of dyslipidemias.
Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
Hypoglycemia
Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormone convertase 2 knockout mice.
Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice.
The efficacy of glycemic control with continuous glucose monitoring on atheroma progression: rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL).
Hypogonadism
Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene.
Hypophosphatemia, Familial
PCSK9 in diabetic kidney disease.
Hypothyroidism
A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism.
Association of serum proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) level with thyroid function disorders.
Cellular colocalization and coregulation between hypothalamic pro-TRH and prohormone convertases in hypothyroidism.
Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.
The influence of subclinical hypothyroidism on serum lipid profile, PCSK9 levels and CD36 expression on monocytes.
Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
Infections
A Genetic Approach to the Association Between PCSK9 and Sepsis.
A Molecular Sensor To Characterize Arenavirus Envelope Glycoprotein Cleavage by Subtilisin Kexin Isozyme 1/Site 1 Protease.
Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units.
Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children.
Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir.
Comparison of cytokine profiles induced by nonlethal and lethal doses of influenza A virus in mice.
Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes.
Differential Expression of PCSK9 Modulates Infection, Inflammation and Coagulation in a Murine Model of Sepsis.
Fatal Recurrent Staphylococcus aureus Infection in a Patient With an Aortic Endostent Under Alirocumab.
Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity.
Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors.
Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naïve patients from the ANRS COPANA cohort.
Inactivation of Kex2p diminishes the virulence of Candida albicans.
Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis.
Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration.
Indirect regulation of PCSK9 gene in inflammatory response by Porphyromonas gingivalis infection.
Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children.
PCSK9 and infection: A potentially useful or dangerous association?
PCSK9 at the crossroad of cholesterol metabolism and immune function during infections.
PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression.
PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement.
PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma.
PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort.
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Porcine Reproductive and Respiratory Syndrome Virus Antagonizes PCSK9's Antiviral Effect via Nsp11 Endoribonuclease Activity.
Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A.
Quantitative and qualitative lipid improvement with chronic hepatitis C virus eradication using direct-acting antivirals.
Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy.
Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality.
Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1? in normolipidemic mice.
Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel anti-viral strategy against arenaviruses.
The immune functions of PCSK9: Local and systemic perspectives.
The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis.
The Plasma Level of Proprotein Convertase FURIN in Patients with Suspected Infection in the Emergency Room: A Prospective Cohort Study.
The role of furin in papillomavirus infection.
The role of PCSK9 in infectious diseases.
Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.
[Hepatitis B virus-mediated effects on host expression of the proprotein convertase Furin].
[Study on a putative, proprotein convertase-cleaved product of HBV core protein in vitro].
Infertility
Lack of varied endometrial expression of proprotein convertase 6 in infertile women with minimal grade endometriosis and idiopathic infertility.
Influenza in Birds
Inhibition of furin/PC-catalyzed surface and intracellular processing by small molecules.
Influenza, Human
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Insulin Resistance
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study.
Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina.
Calorically restricted diets decrease PCSK9 in overweight adolescents.
Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders.
Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis.
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study.
Depression and cardiovascular risk-association among Beck Depression Inventory, PCSK9 levels and insulin resistance.
Erratum to: Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves.
Hypercholesterolemia: The role of PCSK9.
Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients.
Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic alpha-cells in mouse models of beta-cell regeneration.
Medical Management for Secondary Stroke Prevention.
Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors.
PCSK9 and Lp(a) levels of children born after assisted reproduction technologies.
PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.
PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program.
Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance.
Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
Proprotein Convertase Subtilisin/Kexin type 9 affects insulin but not lipid metabolism in cystic fibrosis.
Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
Rescue effect of sodium acetate in diabetes mellitus-associated testicular dysfunction is accompanied by PCSK9 modulation.
Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human.
Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
Serum protein signature of coronary artery disease in type 2 diabetes mellitus.
Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
The comparative effects of high dose atorvastatin and proprotein convertase subtilisin/kexin type 9 inhibitor on the mitochondria of oxidative muscle fibers in obese-insulin resistant female rats.
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.
The role of proprotein convertase subtilisin/kexin type-9 concentration and paraoxonase 1 activities in the blood of women with polycystic ovary syndrome.
The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model.
Insulinoma
Identification of a human insulinoma cDNA encoding a novel mammalian protein structurally related to the yeast dibasic processing protease Kex2.
Insulin and Glucagon mRNA Expression and Prohormone Convertase Immunoreactivity in Normal and Neoplastic Pancreatic Endocrine Tissue.
Peak stimulated insulin secretion is associated with specific changes in gene expression profiles in sporadic insulinomas.
Intermittent Claudication
Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: The CAVASIC study.
Intracranial Arteriosclerosis
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene Is a Risk Factor of Large-Vessel Atherosclerosis Stroke.
Intracranial Hemorrhages
The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis.
Ischemic Stroke
Associations for BCO2, PCSK9, and TR1B1 Polymorphism and Lifestyle Factors with Ischemic Stroke: A Nested Case-Control Study.
Cholesterol and stroke: Roll of PCSK9 inhibitors.
Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations.
Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes.
Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.
Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort.
Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk.
Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.
Lipid metabolism genes in stroke pathogenesis: The Atherosclerosis.
Lipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease.
Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation.
Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
Neurological Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Direct Comparisons.
PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Hyperglycemic Mice Increases the Risk of Hemorrhagic Transformation of Ischemic Stroke.
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke: PheWAS, TreWAS, and More.
PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab.
PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort.
PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene Is a Risk Factor of Large-Vessel Atherosclerosis Stroke.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders.
Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance.
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis.
Kallmann Syndrome
Genetics of hypogonadotropic hypogonadism.
kexin deficiency
A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
A New Case of PCSK1 Pathogenic Variant With Congenital Proprotein Convertase 1/3 Deficiency and Literature Review.
A novel mutation of PCSK1 responsible for PC1/3 deficiency in two siblings.
Association of Exome Sequences With Cardiovascular Traits Among Blacks in the Jackson Heart Study.
Case Report: Complete Maternal Uniparental Isodisomy of Chromosome 5 (iUPD(5)mat) With PCSK1 Nonsense Variant in an Infant With Recurrent Diarrhea.
Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice.
Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort.
Differential Expression of PCSK9 Modulates Infection, Inflammation and Coagulation in a Murine Model of Sepsis.
Disproportionate Hyperproinsulinemia, ?-Cell Restricted Prohormone Convertase 2 Deficiency, and Cell Cycle Inhibitors Expression by Human Islets Transplanted into Athymic Nude Mice: Insights into Nonimmune-Mediated Mechanisms of Delayed Islet Graft Failure.
Disproportionate hyperproinsulinemia, beta-cell restricted prohormone convertase 2 deficiency, and cell cycle inhibitors expression by human islets transplanted into athymic nude mice: insights into nonimmune-mediated mechanisms of delayed islet graft failure.
Early Clinical Diagnosis of PC1/3 Deficiency in a Patient With a Novel Homozygous PCSK1 Splice-Site Mutation.
Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function.
Enteroendocrine Dysfunction in Two Saudi Sisters.
From diarrhea to obesity in prohormone convertase 1/3 deficiency: age-dependent clinical, pathologic, and enteroendocrine characteristics.
Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity.
Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3.
Long-Term Follow-up of a Case with Proprotein Convertase 1/3 Deficiency: Transient Diabetes Mellitus with Intervening Diabetic Ketoacidosis During Growth Hormone Therapy.
Low serum nesfatin-1 levels may be a contributing factor for monogenic obesity due to prohormone convertase 1 deficiency.
Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency.
New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects.
Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease.
Paired box 6 (PAX6) regulates glucose metabolism via proinsulin processing mediated by prohormone convertase 1/3 (PC1/3).
PC1/3 Deficiency Impacts Pro-opiomelanocortin Processing in Human Embryonic Stem Cell-Derived Hypothalamic Neurons.
PCSK1 Variants and Human Obesity.
PCSK9 at the crossroad of cholesterol metabolism and immune function during infections.
PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction.
PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.
PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.
PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction.
PCSK9 deficiency unmasks a sex/tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.
PCSK9 deficiency: A double-edged sword?
PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
PCSK9 inhibitors for treating hypercholesterolemia.
Pcsk9 Knockout Aggravated Experimental Apical Periodontitis via LDLR.
Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice.
Proprotein Convertase 1/3 Deficiency.
Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia.
Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
Proprotein convertase subtilisin/kexin type 9 regulates the production of acute-phase reactants from the liver.
Role of PCSK9 in the Development of Mouse Periodontitis Before and After Treatment: A Double-Edged Sword.
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
Kidney Diseases
Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients.
Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy.
Proprotein convertase subtilisin/kexin type 9 in kidney disease.
Kidney Failure, Chronic
Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease.
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.
PCSK9 in chronic kidney disease.
Proprotein convertase subtilisin/kexin type 9 and mortality in patients starting hemodialysis.
Switching from lipoprotein apheresis to evolocumab in FH siblings on hemodialysis: case reports and discussion.
Up-regulation of Hnf1? gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations.
Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure.
Leukemia
Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis.
Local regulation of implantation at the human fetal-maternal interface.
Lipid Metabolism Disorders
Imperatae rhizoma-Hedyotis diffusa Willd. herbal pair alleviates nephrotic syndrome by integrating anti-inflammatory and hypolipidaemic effects.
Lipodystrophy
One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes.
lipoprotein lipase deficiency
[Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
Liver Cirrhosis
Curcumin Protects Against Intestinal Origin Endotoxemia in Rat Liver Cirrhosis by Targeting PCSK9.
E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver.
Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 Ameliorates Liver Fibrosis via Mitigation of Intestinal Endotoxemia.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis.
Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy.
Liver Cirrhosis, Alcoholic
Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis.
Liver Diseases
A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
Decreased PCSK9 expression in human hepatocellular carcinoma.
Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice.
Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease.
Molecular diagnosis of hypobetalipoproteinemia: an ENID review.
PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma.
PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD.
PCSK9: an emerging target for treatment of hypercholesterolemia.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis.
Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis.
Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function.
Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality.
The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
Liver Diseases, Alcoholic
PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease.
Lung Neoplasms
A meta-analysis and bioinformatics exploration of the diagnostic value and molecular mechanism of miR-193a-5p in lung cancer.
FTO Facilitates Lung Adenocarcinoma Cell Progression by Activating Cell Migration Through mRNA Demethylation.
Local pulmonary opioid network in patients with lung cancer: a putative modulator of respiratory function.
PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways.
Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer.
Lupus Erythematosus, Systemic
Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus.
PCSK9 and inflammation. Maybe a role in autoimmune diseases? Focus on rheumatoid arthritis and systemic lupus erythematosus.
Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus.
Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus.
[Elevated level of serum PCSK9 in patients with systemic lupus erythematosus].
Lupus Nephritis
Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus.
Lymphoma
A new member of the proprotein convertase gene family (LPC) is located at a chromosome translocation breakpoint in lymphomas.
Binding of BiP to the processing enzyme lymphoma proprotein convertase prevents aggregation, but slows down maturation.
Biosynthesis, distinct post-translational modifications, and functional characterization of lymphoma proprotein convertase.
Dynamic palmitoylation of lymphoma proprotein convertase prolongs its half-life, but is not essential for trans-Golgi network localization.
Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis.
The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review).
Malaria
Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children.
Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children.
The role of PCSK9 in infectious diseases.
Malnutrition
Maternal undernutrition during the first week after conception results in decreased expression of glucocorticoid receptor mRNA in the absence of GR exon 17 hypermethylation in the fetal pituitary in late gestation.
Melanoma
Effects of immunisation against PCSK9 in mice bearing melanoma.
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
Proprotein convertase subtilisin/kexin Type 9 is required for Ahnak-mediated metastasis of melanoma into lung epithelial cells.
Metabolic Diseases
Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population.
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.
Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
Metabolic Syndrome
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association Between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and the Presence of Metabolic Syndrome in a Predominantly Rural-Based Sub-Saharan African Population.
Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina.
Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?
Circulating PCSK9 concentrations are increased in postmenopausal women with the metabolic syndrome.
Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis.
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study.
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.
Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9.
Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome.
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
Erratum to: Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
INSIG2 gene polymorphism is associated with higher blood pressure and triglyceride levels in Brazilian obese subjects.
Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data.
Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.
Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.
Proposal of a novel diabetogenic mechanism involving the serpin PAI-1.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
The effect of proprotein convertase subtilisin-kexin type 9 and its inhibition on glucose metabolism and cardiovascular risk. We should do better the second time after statins.
Microcephaly
Interstitial 1p32.1p32.3 deletion in a patient with multiple congenital anomalies.
Muscular Diseases
Hypercholesterolemia treatment in a patient with family hypercholesterolemia and myopathy due to carnitine palmitoyltransferase II deficiency with PCSK9 inhibitors.
PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.
Proprotein Convertase Subtilisin/Kexin Type 9 Antibody and Statin-Associated Autoimmune Myopathy.
Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab (Praluent).
Use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Statin-Associated Immune-Mediated Necrotizing Myopathy: A Case Series.
Myalgia
Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies.
Myocardial Infarction
A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction.
A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterolemia Phenotype Caused by Possibly Oligogenic Variants of the PCSK9 and ABCG5 Genes and Type I CD36 Deficiency.
Acute-Phase Plasma PCSK9 Levels and Recurrent Cardiovascular Events in a Chinese Acute Myocardial Infarction Cohort.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial.
Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition.
Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab.
Blood lipid-related low-frequency variants in LDLR and PCSK9 are associated with onset age and risk of myocardial infarction in Japanese.
Cholesterol-Lowering Agents.
Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway.
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.
Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl.
Correction to: PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Cost-effectiveness of PCSK9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.
Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.
Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.
Effect of protein convertase subtilisin/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population.
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population.
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients.
Evaluation of plasma PCSK9 concentrations, transcript of LDL receptor, as well as the total number of monocyte LDL receptors in acute coronary syndrome patients.
Genetic polymorphisms that predict outcome and need for treatment in cardiovascular disease.
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease.
Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.
Lipid management in people with peripheral artery disease.
Meta-analysis of randomized clinical trials comparing PCSK9 monoclonal antibody versus ezetimibe/placebo in patients at high cardiovascular risk.
Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes.
More- Versus Less-Intensive Lipid-Lowering Therapy.
PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.
PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation.
PCSK9 inhibition could be effective for acute myocardial infarction.
PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab.
PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.
Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction.
PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction.
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
PCSK9 Monoclonal Antibodies: An Overview.
PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
PCSK9 regulates pyroptosis via mtDNA damage in chronic myocardial ischemia.
PCSK9: Associated with cardiac diseases and their risk factors?
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.
Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.
Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction.
Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies.
Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study.
Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials.
Prognostic value of PCSK9 levels in patients with non-ST elevation myocardial infarction undergoing percutaneous coronary intervention (PCI).
Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.
Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.
Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction.
Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study.
Secretome Analysis of Cardiomyocytes Identifies PCSK6 as a Novel Player in Cardiac Remodeling After Myocardial Infarction.
Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review.
Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction.
Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab.
[Clinical study FOURIER].
[Predictive value of plasma PCSK9 levels in acute myocardial infarction patients without reperfusion therapy for recurrence of cardiovascular events within 1 year].
Myocardial Ischemia
Both Rare and Common Variants in PCSK9 Influence Plasma Low-Density Lipoprotein Cholesterol Level in American Indians.
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients.
Hypercholesterolemia treated with a PCSK9 inhibitor in a patient with ischemic heart disease and McArdle disease.
Investigating pleiotropic effects of statins on ischemic heart disease in the UK Biobank using Mendelian randomisation.
PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease.
PCSK9 and inflammation: Role of shear stress, pro-inflammatory cytokines and LOX-1 4.
PCSK9 expression in the ischemic heart and its relationship to infarct size, cardiac function and development of autophagy.
PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses.
PCSK9 regulates pyroptosis via mtDNA damage in chronic myocardial ischemia.
Myositis
Lipid-lowering Therapies in Myositis.
Myotonic Dystrophy
Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab (Praluent).
Nasal Polyps
Overexpressed PC1/3 induces an epithelial-mesenchymal transition in airway epithelium.
Nasopharyngeal Carcinoma
PACE4 Expression is a Novel Independent Prognostic Factor in Nasopharyngeal Carcinoma.
Neoplasm Metastasis
Abnormal expression and processing of the proprotein convertases PC1 and PC2 in human colorectal liver metastases.
Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis.
Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6).
ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis.
Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors.
Furin promotes epithelial-mesenchymal transition in pancreatic cancer cells via Hippo-YAP pathway.
Inhibition of furin/PC-catalyzed surface and intracellular processing by small molecules.
PACE4 regulates apoptosis in human prostate cancer cells via endoplasmic reticulum stress and mitochondrial signaling pathways.
Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis.
Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer.
Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
Proprotein convertase subtilisin/kexin Type 9 is required for Ahnak-mediated metastasis of melanoma into lung epithelial cells.
Proprotein Convertase Subtilisin/Kexin Type 9 Promotes Gastric Cancer Metastasis and Suppresses Apoptosis by Facilitating MAPK Signaling Pathway Through HSP70 Up-Regulation.
Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway.
Neoplasms
Alterations in gene expression of proprotein convertases in human lung cancer have a limited number of scenarios.
Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.
Blockade of furin activity and furin-induced tumor cells malignant phenotypes by the chemically synthesized human furin prodomain.
Changes in PCSK 9 and apolipoprotein B100 in Niemann-Pick disease after enzyme replacement therapy with olipudase alfa.
Cholesterol uptake and regulation in high-grade and lethal prostate cancers.
Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (Silent Corticotroph Adenomas) and with Cushing's disease.
COVID-19 and cancer: Sailing through the tides.
Cross-talk between LOX-1 and PCSK9 in vascular tissues.
Deciphering molecular consequences of the proprotein convertase 1/3 inhibition in macrophages for application in anti-tumour immunotherapy.
Decreased PCSK9 expression in human hepatocellular carcinoma.
Differential gene expression profiles of POMC-related enzymes, transcription factors and receptors between non-pituitary and pituitary ACTH-secreting tumors.
Differential Processing of Neuropeptide Proprotein in Human Breast Adenocarcinoma.
Effects of immunisation against PCSK9 in mice bearing melanoma.
Effects of immunization against PCSK9 in an experimental model of breast cancer.
Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6).
ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis.
Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors.
Expression of PACE4 in chemically induced carcinomas is associated with spindle cell tumor conversion and increased invasive ability.
Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE-/- mice.
FURIN correlated with immune infiltration serves as a potential biomarker in SARS-CoV-2 infection-related lung adenocarcinoma.
Furin expression in squamous cell carcinomas of the oral cavity and other sites evaluated by tissue microarray technology.
Furin mediates brain-derived neurotrophic factor upregulation in cultured rat astrocytes exposed to oxygen-glucose deprivation.
Furin promotes epithelial-mesenchymal transition in pancreatic cancer cells via Hippo-YAP pathway.
Genetic polymorphisms that predict outcome and need for treatment in cardiovascular disease.
Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression.
GOLM1 silencing inhibits the proliferation and motility of human glioblastoma cells via the Wnt/?-catenin signaling pathway.
Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9).
Hydroxychloroquine enhances the antitumor effects of BC001 in gastric cancer.
Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans-Golgi network to the cell surface.
Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes.
Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays.
Immunocytochemical localization of prohormone convertase 1/3 and 2 in pancreatic islet cells and islet cell tumors.
Immunohistochemical expressions of prohormone convertase (PC)1/3 and PC2 in carcinoids of various organs.
Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey.
Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines.
Indirect regulation of PCSK9 gene in inflammatory response by Porphyromonas gingivalis infection.
Inhibition of furin by bone targeting superparamagnetic iron oxide nanoparticles alleviated breast cancer bone metastasis.
Inhibition of furin/PC-catalyzed surface and intracellular processing by small molecules.
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.
Inhibition of pro-protein convertase subtilisin/kexin type 6 has a protective role against synovitis in a rat model of rheumatoid arthritis.
Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates 2,4,6-trinitrobenzenesulfonic acid-induced colitis via repressing toll-like receptor 4/nuclear factor-kappa B.
Inhibition of Tumor Cells Proliferation and Migration by the Flavonoid Furin Inhibitor Isolated From Oroxylum indicum.
Insulin and Glucagon mRNA Expression and Prohormone Convertase Immunoreactivity in Normal and Neoplastic Pancreatic Endocrine Tissue.
Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
Liver-Specific Inactivation of the Proprotein Convertase FURIN Leads to Increased Hepatocellular Carcinoma Growth.
Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls.
Malignant gastric carcinoid causing ectopic ACTH syndrome: discrepancy of plasma ACTH levels measured by different immunoradiometric assays.
Membrane type-1 matrix metalloproteinase functions as a proprotein self-convertase. Expression of the latent zymogen in Pichia pastoris, autolytic activation, and the peptide sequence of the cleavage forms.
Molecular Consequences of Proprotein Convertase 1/3 (PC1/3) Inhibition in Macrophages for Application to Cancer Immunotherapy: A Proteomic Study.
Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing's disease and subclinical Cushing's disease.
PACE4 Expression is a Novel Independent Prognostic Factor in Nasopharyngeal Carcinoma.
PACE4 regulates apoptosis in human prostate cancer cells via endoplasmic reticulum stress and mitochondrial signaling pathways.
PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.
PACE4-based molecular targeting of prostate cancer using an engineered ??Cu-radiolabeled peptide inhibitor.
PCSK9 and cancer: Rethinking the link.
PCSK9 Causes MHC Class I Lysosomal Degradation to Promote Tumor Growth.
PCSK9 inhibition: Not just LDL-Cholesterol knock down: A glimmer for cancer.
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma.
Plasma Purification Treatment Relieves the Damage of Hyperlipidemia to PBMCs.
Polyphenols with indirect proprotein convertase inhibitory activity.
Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report.
Possible relevance between prohormone convertase 2 expression and tumor growth in human adrenocorticotropin-producing pituitary adenoma.
Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer.
Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling.
Processing of high molecular weight form ACTH in human ACTH-secreting tumor cell line (DMS-79) after transfection of prohormone convertase 1/3 gene.
Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis.
Proopiomelanocortin processing and prohormone convertase 1 level in dogs with pituitary corticotroph tumors.
Proprotein convertase 1/3 inhibited macrophages: A novel therapeutic based on drone macrophages.
Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis.
Proprotein convertase subtilisin/kexin type 6 activates the extracellular signal-regulated kinase 1/2 and Wnt family member 3A pathways and promotes in vitro proliferation, migration and invasion of breast cancer MDA-MB-231 cells.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer.
Proprotein convertase subtilisin/kexin Type 9 is required for Ahnak-mediated metastasis of melanoma into lung epithelial cells.
Proprotein Convertase Subtilisin/Kexin Type 9 Promotes Gastric Cancer Metastasis and Suppresses Apoptosis by Facilitating MAPK Signaling Pathway Through HSP70 Up-Regulation.
Proprotein Convertase Subtilisin/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact.
Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway.
Role of PCSK9 in the Development of Mouse Periodontitis Before and After Treatment: A Double-Edged Sword.
Self-Assembly of Amphiphilic Peptides for Recognizing High Furin-Expressing Cancer Cells.
Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence.
Serum Concentrations of Osteogenesis/Osteolysis-Related Factors and Micro-RNA Expression in ST-Elevation Myocardial Infarction.
Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy.
Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.
The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3.
The Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231.
The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.
The proprotein convertase furin in tumour progression.
Transgenic overexpression of the proprotein convertase furin enhances skin tumor growth.
Whole-exome sequencing reveals potential germline and somatic mutations in 60 malignant ovarian germ cell tumors†.
Why don't corticotroph tumors always produce Cushing's disease?
Nephrotic Syndrome
Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome.
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
Effective cholesterol lowering after myocardial infarction in patients with nephrotic syndrome may require a multi-pharmacological approach: a case report.
Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome.
Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome?
Nephrotic syndrome: PCSK9: a target for hypercholesterolaemia in nephrotic syndrome.
PCSK9 in chronic kidney disease.
Plasma PCSK9 in Nephrotic Syndrome and in Peritoneal Dialysis: A Cross-sectional Study.
Proprotein convertase subtilisin/kexin type 9 in kidney disease.
Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome.
Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report.
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
Treatment of hyperlipidemia with proprotein convertase subtilisin/kexin type 9 inhibitor in a patient with nephrotic syndrome: a case report.
Neural Tube Defects
A comparison of the maternal levels of serum proprotein convertase subtilisin/kexin type 9 in pregnant women with the complication of fetal open neural tube defects.
Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders.
Neurobehavioral Manifestations
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.
Neurodegenerative Diseases
Furin promotes dendritic morphogenesis and learning and memory in transgenic mice.
Inhibition of Prohormone Convertases PC1/3 and PC2 by 2,5-Dideoxystreptamine Derivatives.
PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's Disease.
PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders.
Neuroinflammatory Diseases
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease.
Niemann-Pick Diseases
Evaluation of the Potential Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Niemann-Pick Disease, Type C1.
Non-alcoholic Fatty Liver Disease
A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
Association of Genetic and Environmental Factors with Non-Alcoholic Fatty Liver Disease in a Chinese Han Population.
Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver.
Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis.
Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.
Liver fat accumulation is associated with circulating PCSK9.
Network analyses identify liver-specific targets for treating liver diseases.
PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD.
Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function.
The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease.
The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
Non-ST Elevated Myocardial Infarction
Prognostic value of PCSK9 levels in patients with non-ST elevation myocardial infarction undergoing percutaneous coronary intervention (PCI).
Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction.
The relationship between protein convertase subtilisin kexin type-9 levels and extent of coronary artery disease in patients with non-ST-elevation myocardial infarction.
Obesity
A proprotein convertase subtilisin/kexin type 9 inhibitor provides comparable efficacy with lower detriment than statins on mitochondria of oxidative muscle of obese estrogen-deprived rats.
Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina.
Association of serum proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) level with thyroid function disorders.
Association of the rs6235 variant in the proprotein convertase subtilisin/kexin type 1 (PCSK1) gene with obesity and related traits in a Taiwanese population.
Biochemical and cell biological properties of the human prohormone convertase 1/3 Ser357Gly mutation: a PC1/3 hypermorph.
Cardiology clinic visit increases likelihood of evidence-based cholesterol prescribing in severe hypercholesterolemia.
Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering.
Case Report: Complete Maternal Uniparental Isodisomy of Chromosome 5 (iUPD(5)mat) With PCSK1 Nonsense Variant in an Infant With Recurrent Diarrhea.
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.
Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort.
Defective transport of the obesity mutant PC1/3 N222D contributes to loss of function.
Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing.
Early Clinical Diagnosis of PC1/3 Deficiency in a Patient With a Novel Homozygous PCSK1 Splice-Site Mutation.
Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study.
Endoplasmic reticulum-associated degradation of the mouse PC1/3-N222D hypomorph and human PCSK1 mutations contributes to obesity.
Frequencies of obesity susceptibility alleles among ethnically and racially diverse bariatric patient populations.
From diarrhea to obesity in prohormone convertase 1/3 deficiency: age-dependent clinical, pathologic, and enteroendocrine characteristics.
Functional and clinical relevance of novel and known PCSK1 variants for childhood obesity and glucose metabolism.
Functional consequences of a novel variant of PCSK1.
Gene-gene interactions among genetic variants from obesity candidate genes for nonobese and obese populations in type 2 diabetes.
Genetic and Functional Characterization of PCSK1.
Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity.
High Allelic Burden of Four Obesity SNPs Is Associated With Poorer Weight Loss Outcomes Following Gastric Bypass Surgery.
Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3.
Hypogonadotropic hypogonadism.
Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients.
Inhibition of Prohormone Convertases PC1/3 and PC2 by 2,5-Dideoxystreptamine Derivatives.
Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity.
Long-Term Follow-up of a Case with Proprotein Convertase 1/3 Deficiency: Transient Diabetes Mellitus with Intervening Diabetic Ketoacidosis During Growth Hormone Therapy.
Low serum nesfatin-1 levels may be a contributing factor for monogenic obesity due to prohormone convertase 1 deficiency.
Mice lacking PC1/3 expression in POMC-expressing cells do not develop obesity.
Molecular pathogenesis of Kallmann's syndrome.
Naringin Activates AMPK Resulting in Altered Expression of SREBPs, PCSK9, and LDLR To Reduce Body Weight in Obese C57BL/6J Mice.
Neuroendocrine deregulation of food intake, adipose tissue and the gastrointestinal system in obesity and metabolic syndrome.
Neuropeptide processing and its impact on melanocortin pathways.
Obesity and dyslipidemia.
Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene.
Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.
Obesity Associated with Type 2 Diabetes Mellitus Is Linked to Decreased PC1/3 mRNA Expression in the Jejunum.
Obesity, hyperphagia and increased metabolic efficiency in Pc1 mutant mice.
Obesity, POMC, and POMC-processing enzymes: surprising results from animal models.
PCSK1 Variants and Human Obesity.
PCSK9: Associated with cardiac diseases and their risk factors?
Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults.
Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?
Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are associated with coronary artery disease and cardiovascular risk factors.
Preferential apelin-13 production by the proprotein convertase PCSK3 is implicated in obesity.
Prohormone convertase 1 in obesity, gestational diabetes mellitus, and NIDDM: no evidence for a major susceptibility role.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
Reduced stability and pH-dependent activity of a common obesity-linked PCSK1 polymorphism, N221D.
Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects.
Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
Setmelanotide: First Approval.
The association of common variants in PCSK1 with obesity: a HuGE review and meta-analysis.
The comparative effects of high dose atorvastatin and proprotein convertase subtilisin/kexin type 9 inhibitor on the mitochondria of oxidative muscle fibers in obese-insulin resistant female rats.
The genetics of obesity meets basic cell biology through prohormone convertase 1/3.
The role of the leptin-melanocortin signalling pathway in the control of food intake.
Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
What Do Next-Generation Anti-obesity Medications Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab Mean for Clinical Practice?
[Clinical and genetic aspects of monogenic obesity].
[Genetic abnormalities of regulatory mechanism of appetite]
[Leptin-melanocortin system, body weight regulation and obesity]
[Monogenic human obesity: role of the leptin-melanocortin system in the regulation of food intake and body weight in humans.]
[Monogenic obesity in human].
Obesity, Abdominal
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
Hypercholesterolemia: The role of PCSK9.
Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females.
Obesity, Morbid
Acute and chronic impact of bariatric surgery on plasma LDL cholesterol and PCSK9 levels in patients with severe obesity.
INSIG2 gene polymorphism is associated with higher blood pressure and triglyceride levels in Brazilian obese subjects.
Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
Monogenic disorders of obesity and body fat distribution.
Monogenic forms of obesity and diabetes mellitus.
Relationship of Zonulin with Serum PCSK9 Levels after a High Fat Load in a Population of Obese Subjects.
The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
Osteoarthritis
Proprotein convertase furin inhibits matrix metalloproteinase 13 in a TGF?-dependent manner and limits osteoarthritis in mice.
Osteoarthritis, Knee
A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype.
Ovarian Neoplasms
Analysis of epigenetic alterations to proprotein convertase genes in disease.
ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis.
Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors.
Overweight
Calorically restricted diets decrease PCSK9 in overweight adolescents.
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels Predict Future Cardiovascular Event Risks in Hemodialyzed Black African Patients.
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients.
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
Pancreatic Neoplasms
The non-receptor tyrosine kinase c-Src mediates the PDGF-induced association between Furin and pro-MT1-MMP in HPAC pancreatic cells.
Parasitic Diseases
Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms.
Parkinson Disease
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Novel therapeutic approaches for Parkinson's disease by targeting brain cholesterol homeostasis.
Peptic Ulcer
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
Periapical Periodontitis
Pcsk9 Knockout Aggravated Experimental Apical Periodontitis via LDLR.
Periodontal Diseases
Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey.
Periodontitis
Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.
Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration.
Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey.
Indirect regulation of PCSK9 gene in inflammatory response by Porphyromonas gingivalis infection.
Role of PCSK9 in the Development of Mouse Periodontitis Before and After Treatment: A Double-Edged Sword.
Peripheral Arterial Disease
Anti-inflammatory agents in peripheral arterial disease.
Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9.
Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: The CAVASIC study.
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association.
Letter by Alkhalil Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)".
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)".
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.
Response by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)".
The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
The Evolving Future of PCSK9 Inhibitors.
Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease.
[Peripheral Arterial Disease: When is a PCSK9 Inhibitor Useful?]
Peritonitis
PCSK9 is a critical regulator of the innate immune response and septic shock outcome.
Pituitary ACTH Hypersecretion
Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease.
Proopiomelanocortin processing and prohormone convertase 1 level in dogs with pituitary corticotroph tumors.
Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I--immunohistochemical study.
Pituitary Neoplasms
Chromogranin a processing in human pituitary adenomas and carcinomas: analysis with region-specific antibodies.
Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease.
Localization of prohormone convertases 1/3 and 2 in the human pituitary gland and pituitary adenomas: analysis by immunohistochemistry, immunoelectron microscopy, and laser scanning microscopy.
Possible relevance between prohormone convertase 2 expression and tumor growth in human adrenocorticotropin-producing pituitary adenoma.
Processing of high molecular weight form ACTH in human ACTH-secreting tumor cell line (DMS-79) after transfection of prohormone convertase 1/3 gene.
Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I--immunohistochemical study.
Pneumococcal Infections
Proprotein convertase subtilisin/kexin type 9 regulates the production of acute-phase reactants from the liver.
Pneumonia
Pneumocystis infection and the pathogenesis of chronic obstructive pulmonary disease.
Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
Vaccine-Induced Immunogenicity and Protection Against Pneumocystis Pneumonia in a Nonhuman Primate Model of HIV and Pneumocystis Coinfection.
Pneumonia, Pneumocystis
Relationship of Pneumocystis antibody responses to paediatric asthma severity.
Polycystic Ovary Syndrome
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome.
The role of proprotein convertase subtilisin/kexin type-9 concentration and paraoxonase 1 activities in the blood of women with polycystic ovary syndrome.
Polyuria
Early Clinical Diagnosis of PC1/3 Deficiency in a Patient With a Novel Homozygous PCSK1 Splice-Site Mutation.
Pre-Eclampsia
Up-regulation of microRNA-135 or silencing of PCSK6 attenuates inflammatory response in preeclampsia by restricting NLRP3 inflammasome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis.
Prediabetic State
Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study.
Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes.
Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance.
Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.
PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy.
Primary Ovarian Insufficiency
Epistasis between polymorphisms in PCSK1 and DBH is associated with premature ovarian failure.
proprotein convertase 1 deficiency
Mice lacking PC1/3 expression in POMC-expressing cells do not develop obesity.
Prostatic Neoplasms
Evaluation of PACE4 isoforms as biomarkers in thyroid cancer.
Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines.
Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells.
Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations.
PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression.
PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.
PACE4-based molecular targeting of prostate cancer using an engineered ??Cu-radiolabeled peptide inhibitor.
Upregulation of PACE4 in Prostate Cancer is not dependent on E2F Transcription Factors.
protein-long-chain fatty-acyl-lysine deacylase (nad+) deficiency
FoxO3 transcription factor and Sirt6 deacetylase regulate LDL-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
Proteinuria
Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome.
Effective cholesterol lowering after myocardial infarction in patients with nephrotic syndrome may require a multi-pharmacological approach: a case report.
Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome.
Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.
PCSK9 in chronic kidney disease.
Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism.
Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
Proteinuria converts hepatic heparan sulfate to an effective proprotein convertase subtilisin kexin type 9 enzyme binding partner.
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.
Psoriasis
Characterization of PCSK9 in the Blood and Skin of Psoriasis.
Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data.
Potentiation of Psoriasis-Like Inflammation by PCSK9.
Proprotein Convertase Subtilisin/Kexin Type 9, Angiopoietin-Like Protein 8, Sortilin, and Cholesteryl Ester Transfer Protein-Friends of Foes for Psoriatic Patients at the Risk of Developing Cardiometabolic Syndrome?
Pulmonary Disease, Chronic Obstructive
Pneumocystis infection and the pathogenesis of chronic obstructive pulmonary disease.
Relationship of Pneumocystis antibody responses to paediatric asthma severity.
Purpura
Gingival Ischemia and Petechiae in a Patient Medicated With PCSK9 Inhibitor for Hypercholesterolemia: An Adverse Drug Event?
receptor protein-tyrosine kinase deficiency
What Do Next-Generation Anti-obesity Medications Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab Mean for Clinical Practice?
Renal Insufficiency
Biomarkers of aortic bioprosthetic valve structural degeneration.
Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.
Renal Insufficiency, Chronic
Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease.
Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes.
Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease.
Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients.
Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering.
Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels Predict Future Cardiovascular Event Risks in Hemodialyzed Black African Patients.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.
Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease.
Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease.
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
Identifying Patients for Nonstatin Therapy.
Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.
PCSK9 in chronic kidney disease.
Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism.
Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population.
Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk.
Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody: a case report.
Up-regulation of Hnf1? gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations.
Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure.
Respiratory Tract Infections
Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality.
Retinal Artery Occlusion
Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study.
Rhabdomyolysis
Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver.
Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.
Rhabdomyosarcoma
The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.
Rhabdomyosarcoma, Alveolar
The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells.
Sarcoma
Candidate Gene Polymorphisms for Diabetes Mellitus, Cardiovascular Disease and Cancer are Associated with Longevity in Koreans.
Scleroderma, Systemic
Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis.
Seizures
Neuropeptides function in a homeostatic manner to modulate excitation-inhibition imbalance in C. elegans.
Sepsis
A Genetic Approach to the Association Between PCSK9 and Sepsis.
Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units.
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
Bridging lipid metabolism and innate host defense.
Differential Expression of PCSK9 Modulates Infection, Inflammation and Coagulation in a Murine Model of Sepsis.
Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases.
Genetic Polymorphisms in Sepsis and Cardiovascular Disease: Do Similar Risk Genes Suggest Similar Drug Targets?
Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors.
Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis.
Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.
Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor.
Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis.
Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor.
PCSK9 and inflammation. Maybe a role in autoimmune diseases? Focus on rheumatoid arthritis and systemic lupus erythematosus.
PCSK9 at the crossroad of cholesterol metabolism and immune function during infections.
PCSK9 inhibitors in sepsis: a new potential indication?
PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study.
PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort.
PCSK9: A Potential Therapeutic Target for Sepsis.
Plasma PCSK9 levels and sepsis severity: an early assessment in the emergency department.
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Survival in Sepsis: Causal Inference Through Human Genetics.
Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients.
Role of lipoproteins and proprotein convertase subtilisin/kexin type 9 in endotoxin clearance in sepsis.
Sepsis: PCSK9 blockade helps clear pathogenic lipids.
Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance.
The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: emphasis on novel proprotein convertase subtilisin kexin number 9 functions and regulation.
The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
The role of PCSK9 in infectious diseases.
Shock, Septic
Disruption of PC1/3 expression in mice causes innate immune defects and uncontrolled cytokine secretion.
Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors.
Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis.
Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis.
New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications.
PCSK9 and infection: A potentially useful or dangerous association?
PCSK9 is a critical regulator of the innate immune response and septic shock outcome.
PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study.
Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients.
The role of PCSK9 in infectious diseases.
The Understanding and Management of Organism Toxicity in Septic Shock.
Skin Neoplasms
T-cell-expressed proprotein convertase FURIN inhibits DMBA/TPA-induced skin cancer development.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Sleep Initiation and Maintenance Disorders
Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.
Small Fiber Neuropathy
Lipids and peripheral neuropathy.
ST Elevation Myocardial Infarction
Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study.
Serum Concentrations of Osteogenesis/Osteolysis-Related Factors and Micro-RNA Expression in ST-Elevation Myocardial Infarction.
Starvation
Regulation of prohormone convertases in hypothalamic neurons: implications for prothyrotropin-releasing hormone and proopiomelanocortin.
Stomach Neoplasms
Proprotein Convertase Subtilisin/Kexin Type 9 Promotes Gastric Cancer Metastasis and Suppresses Apoptosis by Facilitating MAPK Signaling Pathway Through HSP70 Up-Regulation.
Stroke
A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis.
Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab.
Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering.
Characterization of familial hypercholesterolemia in Taiwanese ischemic stroke patients.
Cholesterol and stroke: Roll of PCSK9 inhibitors.
Cholesterol lowering and stroke: no longer room for pleiotropic effects of statins - confirmation from PCSK9 inhibitor studies.
Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT.
Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl.
Correction to: PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention: Another Step Forward.
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Current Status of Dyslipidemia Treatment for Stroke Prevention.
Effect of protein convertase subtilisin/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population.
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events : A meta-analysis of randomized controlled trials.
Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis.
Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.
Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention.
Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.
Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk.
Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.
Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates neuronal apoptosis following focal cerebral ischemia via apolipoprotein E receptor 2 downregulation in hyperlipidemic mice.
Lipid management in people with peripheral artery disease.
Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke.
Management of Hyperlipidemia After Stroke.
Medical Management for Secondary Stroke Prevention.
Meta-analysis of randomized clinical trials comparing PCSK9 monoclonal antibody versus ezetimibe/placebo in patients at high cardiovascular risk.
Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes.
More- Versus Less-Intensive Lipid-Lowering Therapy.
Neurological Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Direct Comparisons.
New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention.
PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention: Another Step Forward.
PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation.
PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab.
PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.
PCSK9 inhibitors: A new era in stroke prevention?
PCSK9 inhibitors: Add-on therapy to reduce stroke risk.
PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort.
PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites.
PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults.
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
PCSK9 Monoclonal Antibodies: An Overview.
PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS).
Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials.
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis.
Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene Is a Risk Factor of Large-Vessel Atherosclerosis Stroke.
Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance.
Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab.
Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Decade?
STATINS IN STROKE PREVENTION: PRESENT AND FUTURE.
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis.
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain.
What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
[Clinical study FOURIER].
Stroke, Lacunar
Alternative Splicing of Putative Stroke/Vascular Risk Factor Genes Expressed in Blood Following Ischemic Stroke Is Sexually Dimorphic and Cause-Specific.
What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
Synovitis
Inhibition of pro-protein convertase subtilisin/kexin type 6 has a protective role against synovitis in a rat model of rheumatoid arthritis.
Tetanus
Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system.
Thromboinflammation
Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?
Thrombophilia
Prognostic value of PCSK9 levels in patients with non-ST elevation myocardial infarction undergoing percutaneous coronary intervention (PCI).
Thrombosis
Correction to: PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.
European Society of Cardiology (ESC) Annual Congress Report From Barcelona 2017.
LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers.
PCSK9 Biology and Its Role in Atherothrombosis.
PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation.
PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.
Thyroid Diseases
The biochemical and genetic diagnosis of lipid disorders.
Unusual genetic variants associated with hypercholesterolemia in Argentina.
Thyroid Neoplasms
Acute TSH stimulation in vivo does not alter serum PCSK9 levels.
Immunocytochemical Localization of Prohormone Convertase 1/3 and 2 in Thyroid C-Cells and Medullary Thyroid Carcinomas.
Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.
Tics
Role of PCSK9 in PCOS.
Triple Negative Breast Neoplasms
Loss of Proprotein Convertase Furin in Mammary Gland Impairs proIGF1R and proIR Processing and Suppresses Tumorigenesis in Triple Negative Breast Cancer.
Loss of the proprotein convertase Furin in T cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer.
Tuberculosis, Multidrug-Resistant
Serum proteins TGFBI, PCSK9, and CCL14 are potential biomarkers for different traditional Chinese medicine syndromes of multidrug-resistant tuberculosis.
Tyrosinemias
In utero CRISPR-mediated therapeutic editing of metabolic genes.
Vaccinia
Cellular localization and role of prohormone convertases in the processing of pro-melanin concentrating hormone in mammals.
Differential processing of proenkephalin by prohormone convertases 1(3) and 2 and furin.
Enzymic characterization in vitro of recombinant proprotein convertase PC4.
In vitro characterization of the novel proprotein convertase PC7.
Kex2p: a model for cellular endoprotease processing human immunodeficiency virus type 1 envelope glycoprotein precursor.
Role of prohormone convertases in pro-neuropeptide Y processing: coexpression and in vitro kinetic investigations.
Role of prohormone convertases in the tissue-specific processing of proglucagon.
Vascular Diseases
Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome.
Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model.
Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.
Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.
Management of Hyperlipidemia After Stroke.
PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study.
PCSK9 inhibition: ready for prime time in CKD?
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era.
Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.
R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction.
Vascular disease: PCSK9 inhibition in PAD.
Vasculitis
Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.
Venous Thromboembolism
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
Venous Thrombosis
Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice.
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
Viremia
Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes.
Virus Diseases
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level.
How Do Enveloped Viruses Exploit the Secretory Proprotein Convertases to Regulate Infectivity and Spread?
New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications.
PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression.
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
The role of PCSK9 in infectious diseases.
Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.
Xanthomatosis
Achilles Tendon Xanthoma Thickness and Carotid Intima-Media Thickness in a Patient With Heterozygous Familial Hypercholesterolemia on PCSK9 Inhibition: A Case Report and Literature Review.
Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.
Analysis of mutations causing familial hypercholesterolaemia in black South African patients of different ancestr.
Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia.
Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia.
Simplified Canadian Definition for Familial Hypercholesterolemia.
The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study.
[Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].